

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Protocol of the China STEMI Care Project: a 10-year project to improve quality of care by building up the regional STEMI care network

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026362
Article Type:	Protocol
Date Submitted by the Author:	29-Aug-2018
Complete List of Authors:	<p>Zhang, Yan; Peking University First Hospital, Department of Cardiology Yu, Bo; Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, 2nd Affiliated Hospital of Harbin Medical University, Cardiology Han, YL; The General Hospital of Shenyang Military, department of cardiology Wang, Jianan; The Second Affiliated Hospital, Zhejiang University, Department of Cardiology Yang, Lixia; Kunming General Hospital of Chengdu Military Command of PLA, department of cardiology Wan, Zheng; The General Hospital of Tianjin Medical University, department of cardiology Zhang, Zheng; The First Hospital of Lanzhou University, department of cardiology Chen, Yu-guo; Shandong University, Department of Emergency Fu, Xianghua; Shanxi Cardiovascular Hospital, department of cardiology Gao, Chuanyu; Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Cardiology Li, Bao; Shanxi Cardiovascular Hospital, department of cardiology Chen, Ji-yan; Guangdong Cardiovascular Institute, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Cardiology Wu, Ming; Hainan General Hospital, Department of cardiology Ma, Yitong; The First Affiliated Hospital of Xinjiang Medical University, department of cardiology Zhao, Xingsheng; Inner Mongolia People's Hospital, department of cardiology Chen, Yundai; Chinese PLA General Hospital, department of cardiology Yan, Hongbing; Fuwai Hospital, Chinese Academy of Medical Sciences, department of cardiology Xiang, Dingcheng; General Hospital of Guangzhou Military Command of PLA, department of cardiology Fang, Weiyi; Shanghai Chest Hospital, department of cardiology Mehta, Sameer; Lumen Foundation Naber, Christoph K; Stent Save a Life Ge, Junbo; Zhongshan Hospital Fudan University, department of cardiology Huo, Yong ; Peking University First Hospital,</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:	Accreditation, chest pain center, network, reperfusion, ST-elevation myocardial infarction

SCHOLARONE™
Manuscripts

1
2
3
4 **Protocol of the China STEMI Care Project: a 10-year project to improve quality**
5
6 **of care by building up the regional STEMI care network**
7
8
9

10 Yan Zhang¹, Bo Yu², Yaling Han³, Jianan Wang⁴, Lixia Yang⁵, Zheng Wan⁶, Zheng
11 Zhang⁷, Yuguo Chen⁸, Xianghua Fu⁹, Chuanyu Gao¹⁰, Bao Li¹¹, Jiyan Chen¹², Ming
12 Wu¹³, Yitong Ma¹⁴, Xingsheng Zhao¹⁵, Yundai Chen¹⁶, Hongbing Yan¹⁷, Dingcheng
13 Xiang¹⁸, Weiyi Fang¹⁹, Sameer Mehta²⁰, Christoph K. Naber²¹, Junbo Ge²², *Yong
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Huo¹, on behalf of China STEMI Care Project (CSCAP) Investigators

1. Department of Cardiology, Peking University First Hospital, Beijing, China
2. Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China
3. Department of Cardiology, The General Hospital of Shenyang Military, Shenyang, Liaoning Province, China
4. Department of Cardiology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
5. Department of Cardiology, Kunming General Hospital of Chengdu Military Command of PLA, Kunming, Yunnan Department of Cardiology,
6. Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China
7. Department of Cardiology, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, China

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8. Department of Emergency, Qilu Hospital of Shandong University, Jinan, Shandong Province, China
9. Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
10. Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou, Henan Province, China
11. Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi Province, China
12. Department of Cardiology, Guangdong General Hospital, Guangzhou, Guangdong Province, China
13. Department of Cardiology, Hainan General Hospital, Haikou, Hainan Province, China
14. Department of Cardiology, The First Affiliated Hospital of Xinjiang Medical University, Urumchi, The Xinjiang Uygur Autonomous Region, China
15. Department of Cardiology, Inner Mongolia People's Hospital, Hohhot, The Inner Mongolia Autonomous Region, China
16. Department of Cardiology, Chinese PLA General Hospital, Beijing, China
17. Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China
18. Department of Cardiology, General Hospital of Guangzhou Military Command of PLA, Guangzhou, Guangdong Province, China
19. Department of Cardiology, Shanghai Chest Hospital, Shanghai, China

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

20. Lumen Foundation, Miami, USA

21. Stent Save a Life, Paris, France

22. Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai,
China

Running title: Protocol of 10-year China STEMI Care Project

Corresponding author: Yong Huo, MD

Peking University First Hospital, Department of Cardiology

8 Xishiku St, Xicheng District, Beijing, China, 100035

Email: huoyong@263.net.cn

Phone: 86-10-83572283

Fax: 86-10-66137748

Date:

This project was initialed in 2011 and will be finished in 2021.

Abstract

Introduction: The China STEMI (ST-elevation myocardial infarction) Care Project (CSCAP) aimed to improve the reperfusion treatment rate and shorten the total duration of myocardial ischemia by establishing a regional STEMI treatment network covering the whole city region, whole city population, and whole disease processes step by step.

Methods and analysis: This is a prospective, multicenter registry involving three stages. And the CSCAP included 18 provinces, 4 municipalities, and 2 autonomous regions in China. Patients with STEMI who met with the third acute myocardial infarction definition of 2012 and the Chinese STEMI diagnosis and treatment guidelines were enrolled. Phase 1 focused on the in-hospital process optimization of primary percutaneous coronary intervention (PPCI) hospitals; phase 2 on the PPCI hospital-based regional STEMI transfer network, including emergency medical services and non-PPCI hospitals; and phase 3 on the whole-city STEMI care network construction by promoting chest pain center accreditation. Systematic data collection, assessment of quality of care, and subsequent improvement were implemented throughout the project to continuously improve the quality of care for patients with STEMI in the project.

Ethics and dissemination: CSCAP, with the establishment of an intrinsic feedback and certification system, will provide a tailored and continuous quality of STEMI care improvement plan based on the conditions of different regions to further integrate the STEMI care network nationwide.

1
2
3
4
5
6 **Key words:** Accreditation, chest pain center, network, reperfusion, ST-elevation
7
8 myocardial infarction
9

10 11 12 13 **Strengths and limitations of this study** 14

15
16 CSCAP is the first project that focused on establishing a regional STEMI emergency
17
18 care network in China, which will help to understand the condition of STEMI care in
19
20 China extensively. Moreover, quality of STEMI care will be optimized through
21
22 in-hospital process optimization, PPCI hospital-based regional STEMI transfer
23
24 network construction, and the whole-city STEMI care network construction step by
25
26 step. However, hospitals in CSCAP were not randomly selected, which might be
27
28 because of lack of representatives to some degree. Alternatively, it will provide a
29
30 tailored quality of care improvement plan based on the conditions of different regions.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The disease burden of cardiovascular diseases is increasing, posing a major public health issue in China. China will have another 75 million patients with myocardial infarction in the next 15 years with the increasing risk factors and aging population [1]. The Chinese cardiovascular report in 2016 showed an increase in both the hospitalization ratio and mortality of acute myocardial infarction (AMI) over the years. The mortality of AMI is higher in rural areas than in the city, and the younger population is most vulnerable [2].

Acute ST-elevation myocardial infarction (STEMI), mainly caused by a sudden obstruction of the coronary artery with thrombus, benefits from both increasing reperfusion rate and shortening of the duration from the symptom occurrence to the opening of the target vessel [3 4]. Although implementing evidence-based medicine significantly improves the prognosis of patients with STEMI, the gap of the translational application is still large in real-world settings [5]. A majority of Chinese patients with STEMI miss the optimal treatment timing due to restrictions from both patients and medical services [6]. Additionally, the ratio of significant deficiency in STEMI reperfusion treatment remained at the level of around 55% in the last decade; hence, the in-hospital mortality has not changed significantly yet [7].

The effective treatment of STEMI is a systematic issue, and the solution is neither a novel thrombolytic drug nor an intervention device. It can be brought about by comprehensive factors, including patient health awareness, physician level, physician–patient relationship, medical reimbursement system, prehospital emergency

1
2
3
4 system, in-hospital treatment, connection mechanism between prehospital and
5
6 in-hospital care, and posthospital management. Successful experiences from both
7
8 American Lifeline program and the European Stent – Save a Life can be used for
9
10 reference. The quality of medical service can be significantly improved when regional
11
12 STEMI care network is established through close collaboration at different levels of
13
14
15 hospitals and the emergency medical system (EMS) [8 9].
16
17

18
19 China has gradually increased the input of medical insurance in the last few
20
21 decades. However, how to implement the best treatment for STEMI, keeping in mind
22
23 the differences in geographical, humanistic, and medical insurance policy coverage,
24
25 still needs to be discussed. At present, little information exists about whether the
26
27 foreign STEMI guide is difficult to be widely used in China because of the differences
28
29 between the East and the West. Therefore, more evidence from China is needed.
30
31

32
33 Although large-scale studies on AMI or acute coronary syndrome (ACS), such as
34
35 CPACS, CCC, China-PEACE, and CAMI, have been conducted in China, none
36
37 focused on establishing a regional STEMI emergency care network [7 10-12]. Serial
38
39 documents issued by the National Health Commission of China provided favorable
40
41 government support and further emphasized the importance of the administrative
42
43 departments of health care at all levels in strengthening the construction of the
44
45 regional emergency medical treatment system [13-15].
46
47
48
49

50
51 This study aimed to introduce the protocol of a 10-year project named as China
52
53 STEMI Care Project (CSCAP), including objective, organization, procedures, data
54
55 collection, assessment and feedback, and updates. The results provided important
56
57

1
2
3 evidence for the improvement in STEMI care within the whole region and also useful
4
5 information when building up STEMI network in other similar regions.
6
7
8
9

10 **Methods and analysis**

11 **Objectives**

12
13
14
15 CSCAP aimed to build up different types of integrated regional STEMI care
16 network covering the whole city region, city population, and disease processes
17 according to different conditions nationwide. It also aimed to improve the awareness
18 of public health and emergency treatment for patients with STEMI, increase the ratio
19 of reperfusion treatment, shorten the overall duration of myocardial ischemia, and
20 implement standard secondary prevention to improve the long-term prognosis through
21 the establishment and optimization of medical care assessment and feedback system
22 with data support.
23
24
25
26
27
28
29
30
31
32
33
34

35 **Study design**

36
37 CSCAP was a prospective, multicenter registry involving three stages. Phase 1 of
38 CSCAP (CSCAP-1) focused on the in-hospital process optimization of primary
39 percutaneous coronary intervention (PPCI) hospitals. Phase 2 of CSCAP (CSCAP-2)
40 focused on the PPCI hospital-based regional STEMI transfer network construction
41 with their adjacent non-PPCI hospitals and EMS. Phase 3 of CSCAP (CSCAP-3)
42 focused on the whole-city STEMI care network construction by promoting chest pain
43 center (CPC) accreditation (Figure 1). Systematic data collection, assessment of
44 quality of care, and subsequent improvement were implemented throughout this study
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 to continuously improve the quality of care.
4
5

6 **Organizational framework**

7

8 CSCAP was established by the Chinese Physician Association and supported by
9
10 the National Health Commission of China in 2011. After collaborating with the
11
12 European Stent – Save a Life in CSCAP-3, China became its member country in 2017.
13
14 The project office and steering committee were set up for management and academic
15
16 support. Data management and statistical analyses were conducted by the School of
17
18 Public Health of Peking University.
19
20
21

22 **Site selection**

23

24 CSCAP included 18 provinces (Anhui, Fujian, Gansu, Guangdong, Guangxi,
25
26 Hainan, Hebei, Heilongjiang, Henan, Hubei, Jiangsu, Liaoning, Shandong, Shanxi,
27
28 Sichuan, and Zhejiang), 4 municipalities (Beijing, Chongqing, Shanghai, Tianjin, and
29
30 Yunnan), and 2 autonomous regions (Xinjiang and Inner Mongolia) because of the
31
32 high incidence of STEMI in North China and economic issues in South China (Figure
33
34 2).
35
36
37
38
39

40 A total of 53 tertiary hospitals qualified for PPCI in 14
41
42 provinces/municipalities/autonomous regions of China enrolled in CSCAP-1
43
44 (Appendix table 1). These hospitals were selected because they were at the top level
45
46 in their city and potentially a hub for regional network construction in CSCAP-2. A
47
48 total of 241 PCI hospitals with hundreds of adjunct non-PCI hospitals from 24
49
50 provinces/municipalities/autonomous regions were selected to establish the regional
51
52 STEMI care network in CSCAP-2 (Appendix table 1). A total of seven cities (Harbin,
53
54
55
56
57

1
2
3 Hangzhou, Nanning, Qingdao, Shenzhen, Suzhou, and Taiyuan) according to two
4
5
6 different EMS types were selected to build up the whole-city STEMI care network in
7
8
9 CSCAP-3 (Figure 2).

10 **Patient enrollment and follow-up**

11
12
13 Patients with STEMI who met with the third AMI definition in 2012 and the
14
15 Chinese STEMI diagnosis and treatment guidelines were enrolled [16 17]. All patients
16
17 received routine clinical assessments and treatments without any experimental
18
19 intervention. The study was reviewed and approved by the Ethics Board at Peking
20
21 University First Hospital.
22
23

24
25 In CSCAP-1, a total of 4191 patients admitted to hospitals, with symptom onset
26
27 within 12 h regardless of whether receiving reperfusion or symptom onset within
28
29 12–24 h needing PPCI, were enrolled consecutively in 2012. In CSCAP-2, a total of
30
31 20,810 patients with STEMI occurrence within 30 days regardless of reperfusion were
32
33 enrolled consecutively from PPCI hospitals three times at 6-month intervals during
34
35 2015 to 2017. In CSCAP-3, a total of 30 hospitalized patients with symptom onset
36
37 within 30 days were enrolled consecutively from each hospital every 3 months.
38
39 Patients with STEMI were enrolled consecutively from the whole network units,
40
41 including both PCI and non-PCI hospitals. The patients who survived after hospital
42
43 discharge were also followed up for 1 year.
44
45
46
47
48
49

50 **Procedures**

51
52 The treatment flow of the patients with STEMI was based on the STEMI protocol
53
54 of the Announcement of Improving Medical Emergency Treatment Performance of
55
56
57

1
2
3
4 Acute Cardiovascular and Cerebrovascular Diseases released by the National Health
5
6 Commission of China in 2015 [15]. Briefly, this flow chart included 1 center (EMS),
7
8 2 types of hospitals (PCI and non-PCI), 3 types of transport methods (EMS to hospital,
9
10 bypass emergency department (ED), and interhospital), and 11 clinical pathways.
11
12 Different clinical pathways were selected to execute the optimal emergency treatment
13
14 based on the visiting time, method, and hospital level (Figure 3). According to typical
15
16 ischemic symptoms and electrocardiogram (ECG), the procedure was started without
17
18 results of myocardial biomarkers in case of delay.
19
20
21

22 23 **Data collection and management**

24
25 CSCAP collected data of all treatment flow, which were entered into a self-built
26
27 electronic database together with two existing databases of both CPC accreditation
28
29 and national PCI registry by trained clinical research coordinators and clinicians in
30
31 each hospital. Variables included general information of patients, prehospital EMS
32
33 treatment, in-hospital management, and follow-up management (Table 1). The data
34
35 quality was monitored, and suspicious contents by review mainly included missing,
36
37 outlier, and logical error data. When all problems were resolved, the database was
38
39 locked for statistical analysis.
40
41
42
43

44 45 **Key performance index for evaluating the quality of medical care**

46
47 CSCAP mainly used the describing method to rank data quality and medical
48
49 quality. Continuous variables were described as mean (standard deviation) or median
50
51 (interquartile range), while categorical variables were described as percentage. The
52
53 multivariate regression model was used to evaluate the factors related to the
54
55
56
57

1
2
3
4 assessment of medical quality. The Cox model was used to analyze the association
5
6 between the exposures and medical outcomes. A *P* value <0.05 was defined as a
7
8 significant difference. All analyses were performed using R
9
10 (<http://www.R-project.org>).
11
12

13 A total of 13 primary key performance indexes (KPIs) were selected for medical
14
15 quality evaluation based on different roles of EMS and hospitals with or without PCI
16
17 capability in STEMI treatment (Table 2). The circular
18
19 enrollment–evaluation–improvement method was implemented in both CSCAP-2 and
20
21 CSCAP-3. Comparison of KPIs with itself and others was conducted for tailed
22
23 improvements. Quality feedback report contained each KPI of the affiliation and its
24
25 ranking among all affiliations and all regional affiliations, which was presented as
26
27 location in quartile interval without ranking results of others.
28
29
30
31
32
33
34

35 **Ethics and dissemination**

36
37 CSCAP was the first prospective registry study on the establishment of STEMI
38
39 regional care network in China step by step, covering the whole city, population, and
40
41 treatment processes. Some large-scale ACS registry studies have been carried out in
42
43 China, such as the CCC program focusing on the in-hospital treatment of ACS [11],
44
45 the CPACS study focusing on the ACS clinical pathway [10], the CAMI study
46
47 focusing on the hospital treatment of STEMI and non-ST-elevation myocardial
48
49 infarction (NSTEMI) [12], and the China-PEACE study (retrospective study) [7].
50
51 Different from these studies, CSCAP prospectively collected data to analyze the
52
53
54
55
56
57
58
59
60

1
2
3 whole process of STEMI treatment and then provided feedback to units for
4
5
6 problem-guided improvement. This study helped understand the condition of STEMI
7
8 care in China extensively, the gap and differences with other countries, and the issues
9
10 and solutions, leading to optimized clinical practice and improved medical quality.
11
12

13 An integrated regional network mainly contains PCI hospital, non-PCI hospital,
14
15 and EMS. The medical system and patient factors together determine the delay in
16
17 STEMI emergency treatment [18]. Three major types of EMS exist in China: (1)
18
19 independent-type EMS, which has its own ambulances, (2) command-type EMS,
20
21 which does not have its own ambulances and uses local hospital ambulances, and (3)
22
23 affiliate-type EMS, which is based in hospitals and uses its ambulances. On the basis
24
25 of these comprehensive situations, patients may not be transported to the optimal
26
27 hospital to receive effective treatment in the shortest period because of incomplete
28
29 communication [19]. Thus, different types of prehospital information transmission
30
31 should be considered accordingly for hospital alert and rapid and accurate transport.
32
33
34
35
36
37

38 Optimizing the in-hospital green channel can significantly shorten the
39
40 door-to-balloon (D2B) duration, while establishing a CPC was one of the most
41
42 important methods [20 21]. Integration of multiple resources can help in early
43
44 diagnosis, risk stratification, and treatment of STEMI and other acute chest
45
46 pain-related diseases, thus improving efficiency, prognosis, and medical burden.
47
48 Traditional CPC focuses on the optimization and integration of the in-hospital green
49
50 channel aimed to shorten D2B time in STEMI care. The concept of a modern CPC in
51
52 STEMI care expands to establish an effective regional emergency treatment network
53
54
55
56
57
58
59
60

1
2
3 aimed to shorten the total ischemia duration, thus maximizing the advantage of
4 reperfusion therapy. Medical system and patient factors together determine the delay
5
6 of STEMI emergency treatment [18]. Public education for self-awareness
7
8 improvement, which is one of the elements of the CPC construction, could enable
9
10 patients to seek medical assistance promptly in case of suspected myocardial
11
12 infarction, accept timely reperfusion without hesitation, and adhere to primary and
13
14 secondary prevention. CPC independent accreditation in China was initiated in 2013
15
16 with support from the National Health and Family Planning Commission and directed
17
18 by the Chinese Society of Cardiology and the Chinese Physician Association. Two
19
20 types of CPC accreditation standards were developed [22 23], which were separately
21
22 applicable to PCI hospitals and non-PCI hospitals or to relatively small PCI hospitals
23
24 not able to reach the PCI scale. The first standard focused on the improvement in the
25
26 emergency PCI capacity and efficiency, while the second one focused on the
27
28 improvement in thrombolysis and referral capacity to PPCI hospitals. Currently, 460
29
30 accredited CPCs and 2721 hospitals were in the waiting list in China by April 2018.
31
32
33
34
35
36
37
38
39

40 Rapid identification of STEMI and referral to a hospital without PCI certification
41
42 are also important segments in establishing a regional STEMI emergency treatment
43
44 system. A large number of patients with coronary heart disease in China are
45
46 distributed in rural areas, and the mortality of AMI in these regions surpasses the
47
48 urban areas. Although PPCI is the most effective treatment for STEMI, its
49
50 implementation is difficult in most of the primary hospitals, which are limited by
51
52 medical condition, geographic location, and techniques. On the basis of these
53
54
55
56
57
58
59
60

1
2
3 conditions of China, early thrombolysis and transfer PCI strategy are the priorities in
4
5 most of the primary hospitals. Therefore, establishing an effective regional
6
7 collaboration emergency treatment network to improve the treatment quality of
8
9 STEMI is extremely important.
10
11

12
13 The National Cardiovascular Data Registry (NCDR), established since 1997, has
14
15 become the basis for project implementation and quality evaluation as well as
16
17 research center medical quality improvement in the United States. It has a positive
18
19 impact on the clinical practice, medical payment, clinical research, and government
20
21 decision-making [24 25]. The present study referred to the NCDR model to optimize
22
23 the STEMI medical quality and established an assessment and feedback system for
24
25 KPIs, such as efficiency of emergency transport, efficiency of hospital treatment with
26
27 various levels, and cooperation between network units. For KPI selection, PPCI
28
29 hospitals focused on the improvement in the emergency PCI capacity and efficiency;
30
31 non-PPCI hospitals focused on the improvement in rapid diagnosis, thrombolysis, and
32
33 referral capacity to PPCI hospitals; and EMS focused on the improvement in
34
35 information transmission to alert hospitals early for rapid and accurate transport.
36
37
38
39
40
41

42 Since China has a large number of patients, its cardiovascular clinical data
43
44 resource is the largest in the world. However, Chinese guidelines lack high-quality
45
46 evidence. Clinical practice has demonstrated that overseas guidelines and evidence
47
48 may not be applicable to the prevention and treatment of cardiovascular diseases in
49
50 the Chinese population [26]. CSCAP established a database platform for the STEMI
51
52 whole-treatment process, including primary prevention, emergency treatment,
53
54
55
56
57

1
2
3 in-hospital treatment, and secondary prevention. It was a real-world registry study and
4 provided additional information. For example, this study evaluated the compliance of
5 other related cardiovascular guidelines in real clinical practice, tracked the efficacy
6 and side effects of novel drugs and devices, provided evidence for new guidelines,
7 and compared differences among various hospitals and regions.
8
9

10
11
12
13
14
15
16 However, the present study had some limitations. First, CSCAP was expected to
17 record clinical information of the full-treatment procedure of STEMI, which involved
18 many affiliations and departments. Considering the real situation in ED, many time
19 points of the KPIs could not be recorded manually on time, which might have led to
20 missing and inaccurate data. Mobile device app could record the time variables
21 through a simple click and completed the prehospital ECG transmission. Additionally,
22 the auto capture of data gradually became possible to resolve this issue. All of these
23 were considered in this study. Second, hospitals in CSCAP-1 and CSCAP-2 were not
24 strictly selected according to the ratio of PPCI, which might be because of lack of
25 representatives to some degree. The selected hospitals with good conditions were
26 better than the average level in their region. However, the first two phases of CSCAP
27 were not only a description of the current situation of STEMI treatment, but a project
28 to improve the quality of medical care. Therefore, high-level PCI hospitals were
29 suitable to be used as core centers to establish the regional network. These successful
30 experiences might have referral relevance to hospitals in the same region but outside
31 this study, which might be useful for the whole-city network construction in
32 CSCAP-3.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1
2
3 Shortening of the overall ischemia duration and increase in the reperfusion
4 treatment rate are critical issues and challenges in STEMI care. The integration and
5 optimization of a systemic STEMI collaborative network with government support are
6 urgent issues that need to be resolved in China. CSCAP, with the establishment of an
7 intrinsic feedback and certification system, will provide important prospective
8 information for the network construction from PPCI hospital-centered regional
9 network to whole-city covered STEMI transfer network step by step to establish an
10 optimal STEMI care system in China.
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **Authors' contributions**

26
27
28 Yan Zhang coordinated the study, assisted with data collection, performed data
29 analysis, and drafted the manuscript. Bo Yu, Yaling Han, Jianan Wang, Lixia Yang,
30 Zheng Wan, Zheng Zhang, Yuguo Chen, Xianghua Fu, Chuanyu Gao, Bao Li, Jiyan
31 Chen, Ming Wu, Yitong Ma, Xingsheng Zhao, Yundai Chen, Hongbing Yan,
32 Dingcheng Xiang, Weiyi Fang, and Junbo Ge carried out the data collection, and
33 helped to draft the manuscript. Sameer Mehta and Christoph K participated in the
34 design and helped to analyze data and draft the manuscript. Naber, Yong Huo, PI of
35 the project, conceived and designed the project, helped to collect data and draft the
36 manuscript. All authors reviewed the results and approved the final version of the
37 manuscript.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding

CSCAP was funded by Sanofi-Aventis, Abbott, and AstraZeneca.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

The authors thank the members of the study team of all collaborative hospitals and emergency medical services. They are also grateful to the organizations Chinese Medical Doctor Association and China Cardiovascular Association and acknowledge the support provided by the National Health Commission and local governments in China.

Patient consent

Obtained.

Ethics approval

The study was reviewed and approved by the Ethics Board at Peking University First Hospital.

Data sharing statement

No additional data are available.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. Stevens W, Peneva D, Li JZ, et al. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. *BMC health services research* 2016;**16**:175.
2. *Report on cardiovascular disease in China*: Encyclopedia of China Publishing house, 2016.
3. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;**127**:e362-425.
4. Task Force on the management of ST-segment elevation myocardial infarction, Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European heart journal* 2012;**33**:2569-619.
5. Eagle KA, Nallamothu BK, Mehta RH, et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. *European heart journal* 2008;**29**:609-17.
6. Song L, Hu DY, Yan HB, et al. Influence of ambulance use on early reperfusion therapies for acute myocardial infarction. *Chinese medical journal* 2008;**121**:771-5.
7. Li J, Li X, Wang Q, et al. ST-segment elevation myocardial infarction in China

- 1
2
3 from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial
4 Infarction Study): a retrospective analysis of hospital data. *Lancet*
5
6 2015;**385**:441-51.
7
8
9
- 10 8. Jollis JG, Granger CB, Henry TD, et al. Systems of care for ST-segment-elevation
11 myocardial infarction: a report From the American Heart Association's
12 Mission: Lifeline. *Circulation. Cardiovascular quality and outcomes*
13 2012;**5**:423-8.
14
15
16
17
18
19
- 20 9. Kristensen SD, Fajadet J, Di Mario C, et al. Implementation of primary angioplasty
21 in Europe: stent for life initiative progress report. *EuroIntervention : journal of*
22 *EuroPCR in collaboration with the Working Group on Interventional*
23 *Cardiology of the European Society of Cardiology* 2012;**8**:35-42.
24
25
26
27
28
29
- 30 10. Gao R, Patel A, Gao W, et al. Prospective observational study of acute coronary
31 syndromes in China: practice patterns and outcomes. *Heart* 2008;**94**:554-60.
32
33
34
- 35 11. Hao Y, Liu J, Liu J, et al. Rationale and design of the Improving Care for
36 Cardiovascular Disease in China (CCC) project: A national effort to prompt
37 quality enhancement for acute coronary syndrome. *American heart journal*
38 2016;**179**:107-15.
39
40
41
42
43
44
- 45 12. Xu H, Li W, Yang J, et al. The China Acute Myocardial Infarction (CAMI)
46 Registry: A national long-term registry-research-education integrated platform
47 for exploring acute myocardial infarction in China. *American heart journal*
48 2016;**175**:193-201 e3.
49
50
51
52
53
54
- 55 13. Pre-hospital medical emergency management measures. *Chinese Village Medicine*
56
57
58
59
60

- 2014:85-86. (In Chinese)
14. National Health Commission of China. Guiding Principles for Construction and Management of Chest Pain Center (Trial). 2017. (In Chinese)
15. National Health Commission of China. The Announcement of Improving Medical Emergency Treatment Performance of Acute Cardiovascular and Cerebrovascular Diseases. 2015. (In Chinese)
16. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Circulation* 2012;**126**:2020-35.
17. Chinese Society of Cardiology, Editorial board of Chinese Journal of Cardiology. Guidelines for the diagnosis and treatment of acute ST segment elevation myocardial infarction. *Chin J Cardiol* 2015;**43**:380-93.
18. Windecker S, Bax JJ, Myat A, et al. Future treatment strategies in ST-segment elevation myocardial infarction. *Lancet* 2013;**382**:644-57.
19. Ranasinghe I, Rong Y, Du X, et al. System barriers to the evidence-based care of acute coronary syndrome patients in China: qualitative analysis. *Circulation. Cardiovascular quality and outcomes* 2014;**7**:209-16.
20. Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarction. *The New England journal of medicine* 2006;**355**:2308-20.
21. Graff LG, Dallara J, Ross MA, et al. Impact on the care of the emergency department chest pain patient from the chest pain evaluation registry (CHEPER) study. *The American journal of cardiology* 1997;**80**:563-8.

- 1
2
3
4 22. China Chest Pain Center Accreditation Work Committee. Standard for Chinese
5
6 Chest Pain Center accreditation. *Chin J Intervent Cardiol* 2016;**24**:121-30.
7
8
9 23. China Chest Pain Center Accreditation Work Committee. Standard for Chinese
10
11 Primary Chest Pain Center accreditation. *Chin J Intervent Cardiol*
12
13 2016;**24**:131-33.
14
15
16 24. Diercks DB, Kontos MC, Chen AY, et al. Utilization and impact of pre-hospital
17
18 electrocardiograms for patients with acute ST-segment elevation myocardial
19
20 infarction: data from the NCDR (National Cardiovascular Data Registry)
21
22 ACTION (Acute Coronary Treatment and Intervention Outcomes Network)
23
24 Registry. *Journal of the American College of Cardiology* 2009;**53**:161-6.
25
26
27
28 25. Krim SR, Vivo RP, Krim NR, et al. Regional differences in clinical profile, quality
29
30 of care, and outcomes among Hispanic patients hospitalized with acute
31
32 myocardial infarction in the Get with Guidelines-Coronary Artery Disease
33
34 (GWTG-CAD) registry. *American heart journal* 2011;**162**:988-95 e4.
35
36
37
38 26. Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of
39
40 stroke among adults with hypertension in China: the CSPPT randomized
41
42 clinical trial. *Jama* 2015;**313**:1325-35.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. CSCAP data elements

Category	Example elements
Patient baseline information	Demographics (age, sex, ethnicity, occupation, marriage status, medical insurance, and status) Risk factors (smoking status, BMI, hypertension, diabetes, dyslipidemia, peripheral artery disease, prior MI history, prior stroke history, and prior revascularization) Clinical presentation (blood pressure, heart rate, and cardiac function classification)
Prehospital information	Patient (symptoms, symptom onset time, first medical contact method/time, and hospital approaching method) EMS (response time, transfer process, first ECG time, ECG transmission ratio, and bypass ED) Non-PCI hospital (admission time, first ECG time, diagnosis process, reperfusion and other treatment, DI-DO time, and transfer process)
PCI hospital information	Reperfusion (primary PCI, thrombolysis, pharmacoinvasive method and postthrombolysis PCI, indication/contraindication, and nonreperfusion reasons) Treatment delay (hospital approaching method, ED/chest pain center, bypass ED, admission time, first ECG time, catheter lab ready time, D2B, D2N, FMC2B, total ischemic time, and

1
2
3 reasons of delay)

4
5
6 PCI procedures (operative route, coronary angiography
7
8 results, aspiration, culprit vessels, aspiration, stent, and
9
10 elective PCI)

11
12
13 Thrombolytic procedures (thrombolytic agent, dose, and
14
15 outcome)

16
17
18 Medications (loading dose DAPT/statin, antiplatelets,
19
20 β -blockers, statin, ACEI/ARB, GP IIb/IIIa inhibitor, and
21
22 anticoagulant with dose and contraindication information)

23
24
25 Laboratory results (Troponin, CK-MB, creatinine,
26
27 hemoglobin, HbA1C, glucose, BNP, NT-proBNP, lipids, and
28
29 UCG)

30
31
32 Discharge (diagnosis, in-hospital duration, cost, and
33
34 medications)

35
36
37 Outcomes (death, non-fatal reinfarction, bleeding, nonfatal
38
39 stroke, revascularization, and mechanical complication)

40
41
42 Follow-up and management Presentation status (symptom, cardiac function classification,
43
44 blood pressure, heart rate, and follow-up on time ratio)

45
46
47 Laboratory results (lipid profiles, glucose traits, HbA1c,
48
49 creatinine, hemoglobin, BNP, NT-proBNP, ECG, and UCG)

50
51
52 Medications (antiplatelets, β -blockers, statin, and ACEI/ARB)

53
54
55 Risk factor control rate (BP, lipid, glucose, and smoking
56

1
2
3
4 cessation)Outcomes (death, nonfatal reinfarction, stroke,
5
6 revascularization, rehospitalization due to unstable angina
7
8 pectoris, heart failure or other cardiovascular reasons, and
9
10
11 bleeding)
12

13 ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
14
15 BMI, body mass index; BNP, brain natriuretic peptide; CK-MB, creatine kinase MB
16
17 isoenzyme; DAPT, dual antiplatelet therapy; D2B, door to balloon; D2N, door to
18
19 needle; DI-DO, door in-door out; ECG, electrocardiograph; ED, emergency
20
21 department; EMS, emergency medical service; FMC2B, first medical contact to
22
23 balloon; GP IIb/IIIa, glycoprotein IIb/IIIa; HbA1c, glycosylated hemoglobin A1c; MI,
24
25 myocardial infarction; NT-ProBNP, N-terminal pro-brain natriuretic peptide; PCI,
26
27 percutaneous coronary intervention; UCG, ultrasound cardiogram.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Primary performance measures for medical care quality evaluation

Primary performance measures

Prehospital care

Symptom onset to arrival in hospital (min)

Hospital admission ratio via ambulance (%)

Prehospital ECG transmission ratio (%)

Bypass ED ratio in patients with symptom onset within 12 h (%)

Reperfusion

Overall reperfusion ratio (%)

Thrombolysis ratio in patients with symptom onset within 12 h (%)

Primary PCI ratio in patients with symptom onset within 12 h (%)

D2B in patients with symptom onset within 12 h (min)

D2N in patients with symptom onset within 12 h (min)

DischargeUsage of both DAPT, statin, β blocker, and ACEI/ARB in patients without contraindication (%)**Outcomes**

In-hospital mortality (%)

Follow-up and management

1-Year on-time follow-up ratio (%)

1-Year MACE (%) including mortality, non-fatal myocardial infarction, non-fatal stroke, hospitalization due to heart failure or acute coronary syndrome, etc.

ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;

1
2
3 DAPT, dual antiplatelet therapy; D2B, door to balloon; D2N, door to needle; ECG,
4
5 electrocardiogram; ED, emergency department; PCI, percutaneous coronary
6
7 intervention; MACE, major adverse cardiovascular event.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends


Figure 1. CSCAP whole-city STEMI care network construction.

Figure 2. Geographic distribution of CSCAP.

Figure 3. CSCAP STEMI care flow chart.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




CSCAP whole-city STEMI care network construction.

102x62mm (300 x 300 DPI)



Geographic distribution of CSCAP

170x170mm (300 x 300 DPI)



CSCAP STEMI care flow chart.

148x130mm (300 x 300 DPI)

Appendix table 1 Complete list of PCI hospitals participat

Hospital	Province/Municipality/
Chizhou people's hospital	Anhui
Taihe County People's Hospital	Anhui
Anhui Provincial Hospital	Anhui
Maanshan Central Hospital	Anhui
Beijing Anzhen Hospital#	Beijing
Beijing Chao-Yang Hospital#	Beijing
Chinese PLA General Hospital Medical School of Chinese PLA*	Beijing
General Hospital of Armed Police Forces*	Beijing
General Hospital of Beijing Military Command of PLA*	Beijing
Navy General Hospital	Beijing
Peking University First Hospital#	Beijing
Peking University People's Hospital#	Beijing
Peking University Shougang Hospital#	Beijing
Peking University Third Hospital#	Beijing
The 306th Hospital of PLA	Beijing
The 309th Hospital of Chinese People's Liberation Army	Beijing
Daping Hospital,Research Institute of Surgery Third Military Medic	Chongqing
Southwest Hospital	Chongqing
Xinqiao Hospital,Research Institute of Surgery Third Military Medi	Chongqing
Fuzhou General Hospital of Nanjing Military Command	Fujian
Jiuquan people's Hospital of Gansu Province	Gansu
Lanzhou General Hospital of Lanzhou Military Command	Gansu
The First Hospital of Lanzhou University*	Gansu
The First Hospital of Tianshui	Gansu
Dongguan Kanghua Hospital	Guangdong
The Third People's Hospital of Dongguan	Guangdong
The First People's Hospital of Shunde	Guangdong
First Affiliated Hospital of Sun Yat-sen University#	Guangdong
General Hospital of Guangzhou Military Command of PLA	Guangdong
Guangdong General Hospital of Armed Police Force	Guangdong
Guangdong General Hospital*	Guangdong
Guangzhou Red Cross Hospital#	Guangdong
Nanfang Hospital	Guangdong
Wuhan General Hospital of Guangzhou Military Command	Guangdong
Maoming Hospital of TCM	Guangdong
Maoming People's Hospital	Guangdong
Qingyuan people's Hospital	Guangdong
Shantou Central Hospital	Guangdong
The First Affiliated Hospital of Shantou University Medical College	Guangdong
Yuebei People's Hospital	Guangdong
Shenzhen People's Hospital	Guangdong
Sun yat-sen Cardiovascular Hospital of Shenzhen*	Guangdong
The Fourth People's Hospital of Shenzhen	Guangdong
Affiliated Hospital of Guangdong Medical University	Guangdong
Danzhou People's Hospital	Hainan
Haikou people's Hospital	Hainan

1		
2	Hainan General Hospital	Hainan
3	Hainan Provincial Nong Ken Hospital	Hainan
4	The First Affiliated Hospital of Hainan Medical University	Hainan
5	Hainan Branch of PLA General Hospital	Hainan
6	Hainan Third People's Hospital	Hainan
7	Sanya People's Hospital	Hainan
8	Affiliated Hospital of Hebei University	Hebei
9	Baoding Second Central Hospital	Hebei
10	the First Central Hospital of Baoding City	Hebei
11	Cangzhou Central Hospital*	Hebei
12	General Hospital of North China Petroleum Administration Bureau	Hebei
13	Affiliated Hospital of Chengde Medical College	Hebei
14	Chengde Central Hospital	Hebei
15	Handan Central Hospital	Hebei
16	Handan First Hospital	Hebei
17	Harrison international Heping Hospital	Hebei
18	Hengshui Cardiovascular Hospital	Hebei
19	Langfang Fourth People's Hospital	Hebei
20	Qinhuangdao First Hospital	Hebei
21	Bethune International Peace Hospital	Hebei
22	Hebei General Hospital	Hebei
23	The Second Hospital of Hebei Medical University*	Hebei
24	Kailuan General Hospital	Hebei
25	Tangshan Gongren Hospital*	Hebei
26	Xingtai People's Hospital	Hebei
27	Xingtai Third Hospital	Hebei
28	The Second Affiliated Hospital of Hebei North University	Hebei
29	Zhangjiakou First Hospital	Hebei
30	Zunhua people's Hospital	Hebei
31	The Fourth Hospital of Harbin Medical University*	Heilongjiang
32	The Second Affiliated Hospital of Harbin Medical University*	Heilongjiang
33	Daqing Oilfield General Hospital*	Heilongjiang
34	Longnan hospital in Daqing	Heilongjiang
35	Greater Khingan Mountains Aera People's Hospital	Heilongjiang
36	Harbin First Hospital	Heilongjiang
37	The Central Hospital of Jiamusi City	Heilongjiang
38	Mudanjiang Cardiovascular Hospital	Heilongjiang
39	Mudanjiang City 2rd People's Hospital	Heilongjiang
40	The 3rd Affiliated Hospital of Qiqihar Medical University	Heilongjiang
41	Tsitsihar First Hospital	Heilongjiang
42	Shuangyashan Coal General Hospital	Heilongjiang
43	The First Affiliated Hospital of Harbin Medical University#	Helongjiang
44	Anyang District Hospital	Henan
45	The People's Hospital of Hebi	Henan
46	Huaihe Hospital of Henan University	Henan
47	Kaifeng Central Hospital	Henan
48	Luohe Central Hospital	Henan
49	The First Affiliated Hospital of Henan University of Science and Te	Henan
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1		
2	The Second Affiliated Hospital of Henan University of Science and	Henan
3	Nanyang Central Hospital	Henan
4	the Second People's Hospital of Pingdingshan	Henan
5	Puyang Oilfield General Hospital	Henan
6	Puyang People's Hospital	Henan
7	First people's hospital of Shangqiu	Henan
8	Xinxiang Central Hospital	Henan
9	Xuchang Central Hospital	Henan
10		
11	First Affiliated Hospital of Henan University of TCM	Henan
12	Henan Province People's Hospital*	Henan
13	Henan Provincial Chest Hospital	Henan
14	The 7th people's hospital of Zhengzhou	Henan
15	The First Affiliated Hospital of Zhengzhou University*	Henan
16	Zhengzhou first people's hospital	Henan
17	Zhumadian Central Hospital	Henan
18	Alxa League Central Hospital	Inner Mongolia
19	Baotou Central Hospital*	Inner Mongolia
20	The First Affiliated Hospital of Baotou Medical College	Inner Mongolia
21	Bayannur Hospital	Inner Mongolia
22	Chifeng Municipal Hospital	Inner Mongolia
23	The Affiliated Hospital of Chifeng University	Inner Mongolia
24	Inner Mongolia People's Hospital	Inner Mongolia
25	The Affiliated Hospital of Inner Mongolia Medical University	Inner Mongolia
26	Ordos Central Hosiptal	Inner Mongolia
27	Tong Liao City Hospital	Inner Mongolia
28	Ulanqab Central Hospital	Inner Mongolia
29	People's Hospital Wuhai City	Inner Mongolia
30	Xilingol League Hospital	Inner Mongolia
31	Inner Mongolia Xing'an Meng People's Hospital	Inner Mongolia
32	Inner Mongolia Forestry General Hospital	Inner Mongolia
33	Ansteel Group Hospital	Liaoning
34	Dalian Municipal Central Hospital*	Liaoning
35	The First Affiliated Hospital of Dalian Medical University*	Liaoning
36	The Second Hospital of Dalian Medical University	Liaoning
37	Dandong Central Hospital	Liaoning
38	General Hospital Under The Fushun Mining Affairs Bureau	Liaoning
39	Fuxin Central Hospital	Liaoning
40	Huludao Central Hospital	Liaoning
41	Jinzhou Central Hospital	Liaoning
42	The First Affiliated Hospital of Liaoning Medical University*	Liaoning
43	Shengjing Hospital of China Medicine University#	Liaoning
44	The First Affiliated Hospital of Liaoning University of Traditional C	Liaoning
45	The First Hospital of China Medical University	Liaoning
46	The First Hospital of China Medical University	Liaoning
47	The Fourth Hospital of China Medical University*	Liaoning
48	The General Hospital of Shenyang Military	Liaoning
49	The People's Hospital of Liaoning Province*	Liaoning
50	The Second Affiliated Hospital of Shenyang Medical College	Liaoning
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1		
2	Tieling Central Hospital	Liaoning
3	Yingkou Central Hospital	Liaoning
4	Nanjing General Hospital	Nanjing
5	Dezhou People's Hospital	Shandong
6	Dongying People's Hospital	Shandong
7	Jinan Central Hospital	Shandong
8	Qianfo Hill Hospital	Shandong
9	Qilu Hospital of Shandong University*	Shandong
10	Shandong Provincial Hospital*	Shandong
11	The No.4 Hospital 1946 Jinan Shandong	Shandong
12	The Second Hospital of Shandong University	Shandong
13	Jining NO.1 People's Hospital	Shandong
14	The Affiliated Hospital of Jining Medical University*	Shandong
15	Liaocheng People's Hospital*	Shandong
16	The second People's Hospital Of Liaocheng	Shandong
17	Linyi People's Hospital	Shandong
18	Qingdao Central Hospital	Shandong
19	Qingdao Municipal Hospital	Shandong
20	The Affiliated Hospital of Qingdao University*	Shandong
21	Taian City Central Hospital	Shandong
22	The Affiliated Hospital of Taishan Medical University	Shandong
23	Tengzhou Central People's Hospital	Shandong
24	Anqiu City People's Hospital	Shandong
25	The Affiliated Hospital of Weifang Medical University	Shandong
26	Weifang People's Hospital	Shandong
27	Weifang Traditional Chinese Hospital	Shandong
28	Changhai Hospital	Shanghai
29	Jinshan Hospital of Fudan University	Shanghai
30	NO.3 People's Hospital Affiliated to Shanghai Jiao Tong University	Shanghai
31	Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai
32	Ruijin Hospital, Shanghai Jiaotong University	Shanghai
33	Shanghai Changzheng Hospital	Shanghai
34	Shanghai Chest Hospital	Shanghai
35	Shanghai East Hospital	Shanghai
36	Shanghai Fengxian Central Hospital	Shanghai
37	Shanghai General Hospital	Shanghai
38	Shanghai Gongli Hospital	Shanghai
39	Shanghai Jiading District Central Hospital	Shanghai
40	Shanghai Jiao Tong University Affiliated Sixth People's Hospital	Shanghai
41	Shanghai Minhang Central Hospital	Shanghai
42	Shanghai ninth People's Hospital Affiliated to Shanghai Jiaotong University	Shanghai
43	Shanghai Pudong New Area People's Hospital	Shanghai
44	Shanghai Pudong New District Zhoupu Hospital	Shanghai
45	Shanghai Putuo District Central Hospital	Shanghai
46	The Fifth People's Affiliated Hospital of Fudan University	Shanghai
47	The Huashan Hospital of Fudan University	Shanghai
48	The Tenth People's Hospital of Tongji University*	Shanghai
49	Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine	Shanghai
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1		
2	Tongji Hospital	Shanghai
3	Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai
4	Zhongshan Hospital*	Shanghai
5	General hospital of shanxi lu 'an mining (group) co., LTD	Shanxi
6	Shanxi Luan Mining (Group) Co., Ltd. General Hospital	Shanxi
7	With the Coal Group General Hospital*	Shanxi
8	Shanxi Fenyang Hospital	Shanxi
9	Shanxi Province Cardiovascular Disease Hospital*	Shanxi
10	Taiyuan Center Hospital	Shanxi
11	Taiyuan People's Hospital#	Shanxi
12	Tangdu Hospital, The Fourth Military Medical University	Shanxi
13	Xijing Hospital, The Fourth Military Medical University	Shanxi
14	The First People's Hospital of Yangquan	Shanxi
15	The First People's Hospital of JinZhong	Shanxi
16	General Hospital of Chengdu Military Command of PLA	Sichuan
17	Affiliated Hospital of Chinese People's Armed Police Force Logistics Engineering College	Tianjin
18	TEDA International Cardiovascular Hospital*	Tianjin
19	The 254th Hospital of Chinese People's Liberation Army	Tianjin
20	The 254th Hospital of PLA	Tianjin
21	The Affiliated Hospital of Armed Police Medical College#	Tianjin
22	The Second Hospital of Tianjin Medical University*	Tianjin
23	Tianjin Baodi District People's Hospital	Tianjin
24	Tianjin Beichen Hospital	Tianjin
25	Tianjin Chest Hospital*	Tianjin
26	Tianjin Fifth Central Hospital	Tianjin
27	Tianjin First Central Hospital	Tianjin
28	Tianjin Fourth Central Hospital	Tianjin
29	Tianjin Jinghai hospital	Tianjin
30	Tianjin Jixain People's Hospital	Tianjin
31	Tianjin Medical University General Hospital*	Tianjin
32	Tianjin People's Hospital*	Tianjin
33	Tianjin Third Central Hospital	Tianjin
34	Tianjin Xiqing Hospital	Tianjin
35	The First Affiliated Hospital of the Medical College, Shihezi University	Xinjiang
36	People's Hospital of Xinjiang Uygur Autonomous Region*	Xinjiang
37	The First Affiliated Hospital of Xinjiang Medical University*	Xinjiang
38	The Second Affiliated Hospital of Xinjiang Medical University	Xinjiang
39	The Xinjiang Uygur Autonomous Region Hospital of traditional Chinese Medicine	Xinjiang
40	Xinjiang Cardio-Cerebrovascular Disease Hospital	Xinjiang
41	Urumqi General Hospital of Lanzhou Military Area Command	Xinjiang
42	Kunming General Hospital of Chengdu Military Command of PLA	Yunnan
43	Hangzhou First People's Hospital	ZheJiang
44	Sir Run Run Shaw Hospital of ZheJiang University School of Medicine	ZheJiang
45	The Affiliated Hospital of Hangzhou Normal University	ZheJiang
46	The First Affiliated Hospital ZheJiang University*	ZheJiang
47	The Second Affiliated Hospital of ZheJiang University School of Medicine	ZheJiang
48	ZheJiang Provincial Hospital of TCM	ZheJiang
49	ZheJiang Provincial People's Hospital	ZheJiang
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1		
2	Jiaxing First Hospital	ZheJiang
3	Jiaxing Second Hospital	ZheJiang
4	Jinhua Central Hospital	ZheJiang
5	Lishui Central Hospital	ZheJiang
6	Ningbo City Medical Treatment Center Lihuili Hospital	ZheJiang
7	Ningbo First Hospital	ZheJiang
8	Ningbo No.2 Hospital	ZheJiang
9		
10	Quzhou People's Hospital of ZheJiang Province	ZheJiang
11	Shaoxing Second Hospital	ZheJiang
12	Taizhou Central Hospital	ZheJiang
13	Taizhou Hospital of ZheJiang Province	ZheJiang
14	People's Hospital of Wenzhou City	ZheJiang
15	The First Affiliated Hospital of Wenzhou Medical University	ZheJiang
16	The Second Affiliated Hospital and Yuying Children's Hospital of W	ZheJiang
17		
18	Zhuji People's Hospital of ZheJiang Province	ZheJiang
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

ting in CSCAP-1 and CSCAP-2**City**

1
2
3
4 Chizhou
5 Fuyang
6 Hefei
7 Maanshan
8 Beijing
9 Beijing
10 Beijing
11 Beijing
12 Beijing
13 Beijing
14 Beijing
15 Beijing
16 Beijing
17 Beijing
18 Beijing
19 Beijing
20 Beijing
21 Beijing
22 Chongqing
23 Chongqing
24 Chongqing
25 Fuzhou
26 Jiuquan
27 Lanzhou
28 Lanzhou
29 Tianshui
30 Dongguan
31 Dongguan
32 Foshan
33 Guangzhou
34 Guangzhou
35 Guangzhou
36 Guangzhou
37 Guangzhou
38 Guangzhou
39 Guangzhou
40 Guangzhou
41 Guangzhou
42 Maoming
43 Maoming
44 Qingyuan
45 Shantou
46 Shantou
47 Shaoguan
48 Shenzhen
49 Shenzhen
50 Shenzhen
51 Zhanjiang
52 Danzhou
53 Haikou
54
55
56
57
58
59
60

1
2 Haikou
3 Haikou
4 Haikou
5 Sanya
6 Sanya
7 Sanya
8 Sanya
9 Baoding
10 Baoding
11 Baoding
12 Cangzhou
13 Cangzhou
14 Chengde
15 Chengde
16 Chengde
17 Handan
18 Handan
19 Hengshui
20 Hengshui
21 Langfang
22 Qinghuangdao
23 Shijiazhuang
24 Shijiazhuang
25 Shijiazhuang
26 Tangshan
27 Tangshan
28 Tangshan
29 Xingtai
30 Xingtai
31 Xingtai
32 Zhangjiakou
33 Zhangjiakou
34 Zunhua
35 ?Harbin
36 ?Harbin
37 Daqing
38 Daqing
39 Daqing
40 Greater Khingan
41 Harbin
42 Jiamusi
43 Mudanjiang
44 Mudanjiang
45 Qiqihar
46 Qiqihar
47 Qiqihar
48 Shuangyashan
49 Harbin
50 Anyang
51 Hebi
52 Kaifeng
53 Kaifeng
54 Kaifeng
55 Luohe
56 Luoyang
57
58
59
60

1
2 Luoyang
3 Nanyang
4 Pingdingshan
5 Puyang
6 Puyang
7 Shangqiu
8 Xinxiang
9 Xuchang
10 Zhengzhou
11 Zhengzhou
12 Zhengzhou
13 Zhengzhou
14 Zhengzhou
15 Zhengzhou
16 Zhengzhou
17 Zhengzhou
18 Zhumadian
19 Alxa League
20 Baotou
21 Baotou
22 Bayannur
23 Chifeng
24 Chifeng
25 Huhehaote
26 Huhehaote
27 Ordos
28 Tongliao
29 Ulanqab
30 Wuhai
31 Xilinhaote
32 Xing'an Meng
33 Yakeshi
34 Anshan
35 Dalian
36 Dalian
37 Dalian
38 Dandong
39 Fushun
40 Fuxin
41 Huludao
42 Jinzhou
43 Jinzhou
44 Shenyang
45 Shenyang
46 Shenyang
47 Shenyang
48 Shenyang
49 Shenyang
50 Shenyang
51 Shenyang
52 Shenyang
53 Shenyang
54 Shenyang
55 Shenyang
56 Shenyang
57
58
59
60

- 1
- 2 Tieling
- 3 Yingkou
- 4 Nanjing
- 5 Dezhou
- 6 Dongying
- 7 Jinan
- 8 Jinan
- 9 Jinan
- 10 Jinan
- 11 Jinan
- 12 Jinan
- 13 Jinan
- 14 Jining
- 15 Jining
- 16 Liaocheng
- 17 Liaocheng
- 18 Linyi
- 19 Qingdao
- 20 Qingdao
- 21 Qingdao
- 22 Taian
- 23 Taian
- 24 Tengzhou
- 25 Weifang
- 26 Weifang
- 27 Weifang
- 28 Weifang
- 29 Shanghai
- 30 Shanghai
- 31 Shanghai
- 32 Shanghai
- 33 Shanghai
- 34 Shanghai
- 35 Shanghai
- 36 Shanghai
- 37 Shanghai
- 38 Shanghai
- 39 Shanghai
- 40 Shanghai
- 41 Shanghai
- 42 Shanghai
- 43 Shanghai
- 44 Shanghai
- 45 Shanghai
- 46 Shanghai
- 47 Shanghai
- 48 Shanghai
- 49 Shanghai
- 50 Shanghai
- 51 Shanghai
- 52 Shanghai
- 53 Shanghai
- 54 Shanghai
- 55 Shanghai
- 56 Shanghai
- 57
- 58
- 59
- 60

For peer review only

1
2 Shanghai
3 Shanghai
4 Shanghai
5 Changzhi
6 Changzhi
7 Datong
8 Linfen
9 Taiyuan
10 Taiyuan
11 Taiyuan
12 Taiyuan
13 Xi'an
14 Xi'an
15 Yangquan
16 Yuci
17 Chengdu
18 Tianjin
19 Tianjin
20 Tianjin
21 Tianjin
22 Tianjin
23 Tianjin
24 Tianjin
25 Tianjin
26 Tianjin
27 Tianjin
28 Tianjin
29 Tianjin
30 Tianjin
31 Tianjin
32 Tianjin
33 Tianjin
34 Tianjin
35 Tianjin
36 Tianjin
37 Tianjin
38 Tianjin
39 Shihezi
40 Urumchi
41 Urumchi
42 Urumchi
43 Urumchi
44 Urumchi
45 Urumchi
46 Urumqi
47 Kunming
48 Hangzhou
49 Hangzhou
50 Hangzhou
51 Hangzhou
52 Hangzhou
53 Hangzhou
54 Hangzhou
55 Hangzhou
56 Hangzhou
57
58
59
60

- 1
- 2 Jiaxing
- 3 Jiaxing
- 4 Jinhua
- 5 Lishui
- 6 Ningbo
- 7 Ningbo
- 8 Ningbo
- 9 Ningbo
- 10 Quzhou
- 11 Shaoxing
- 12 Taizhou
- 13 Taizhou
- 14 Wenzhou
- 15 Wenzhou
- 16 Wenzhou
- 17 Wenzhou
- 18 Zhuji
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only

BMJ Open

Protocol of the China STEMI Care Project (CSCAP): a 10-year project to improve quality of care by building up a regional STEMI care network

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026362.R1
Article Type:	Protocol
Date Submitted by the Author:	31-Jan-2019
Complete List of Authors:	<p>Zhang, Yan; Peking University First Hospital, Department of Cardiology Yu, Bo; Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, 2nd Affiliated Hospital of Harbin Medical University, Cardiology Han, YL; The General Hospital of Shenyang Military Region, Department of Cardiology Wang, Jianan; The Second Affiliated Hospital, Zhejiang University, Department of Cardiology Yang, Lixia; Kunming General Hospital of Chengdu Military Region, Department of Cardiology Wan, Zheng; The General Hospital of Tianjin Medical University, department of cardiology Zhang, Zheng; The First Hospital of Lanzhou University, department of cardiology Chen, Yu-guo; Qilu Hospital of Shandong University, Department of Emergency Fu, Xianghua; The Second Hospital of Hebei Medical University, Department of Cardiology Gao, Chuanyu; Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Cardiology Li, Bao; Shanxi Cardiovascular Hospital, department of cardiology Chen, Ji-yan; Guangdong Cardiovascular Institute, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Cardiology Wu, Ming; Hainan General Hospital, Department of cardiology Ma, Yitong; The First Affiliated Hospital of Xinjiang Medical University, department of cardiology Zhao, Xingsheng; Inner Mongolia People's Hospital, department of cardiology Chen, Yundai; Chinese PLA General Hospital, department of cardiology Yan, Hongbing; Fuwai Hospital, Chinese Academy of Medical Sciences, department of cardiology Xiang, Dingcheng; Guangzhou General Hospital of Guangzhou Military Region, Department of Cardiology Fang, Weiyi; Shanghai Chest Hospital, department of cardiology Mehta, Sameer; Lumen Foundation Naber, Christoph K; Stent Save a Life Ge, Junbo; Zhongshan Hospital Fudan University, department of cardiology</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Huo, Yong ; Peking University First Hospital,
Primary Subject Heading :	Evidence based practice
Secondary Subject Heading :	Medical management
Keywords :	Accreditation, chest pain center, network, reperfusion, ST-elevation myocardial infarction



Protocol of the China STEMI Care Project (CSCAP): a 10-year project to improve quality of care by building up a regional STEMI care network

Yan Zhang¹, Bo Yu², Yaling Han³, Jianan Wang⁴, Lixia Yang⁵, Zheng Wan⁶, Zheng Zhang⁷, Yuguo Chen⁸, Xianghua Fu⁹, Chuanyu Gao¹⁰, Bao Li¹¹, Jiyan Chen¹², Ming Wu¹³, Yitong Ma¹⁴, Xingsheng Zhao¹⁵, Yundai Chen¹⁶, Hongbing Yan¹⁷, Dingcheng Xiang¹⁸, Weiyi Fang¹⁹, Sameer Mehta²⁰, Christoph K. Naber²¹, Junbo Ge²², *Yong Huo¹, on behalf of China STEMI Care Project (CSCAP) Investigators

1. Department of Cardiology, Peking University First Hospital, Beijing, China
2. Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China
3. Department of Cardiology, The General Hospital of Shenyang Military Region, Shenyang, Liaoning Province, China
4. Department of Cardiology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
5. Department of Cardiology, Kunming General Hospital of Chengdu Military Region, Kunming, Yunnan Department of Cardiology, China
6. Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China
7. Department of Cardiology, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, China

- 1
2
3
4 8. Department of Emergency, Qilu Hospital of Shandong University, Jinan,
5
6 Shandong Province, China
- 7
8
9 9. Department of Cardiology, The Second Hospital of Hebei Medical University,
10
11 Shijiazhuang, Hebei Province, China
- 12
13
14 10. Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou,
15
16 Henan Province, China
- 17
18
19 11. Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi
20
21 Province, China
- 22
23
24 12. Department of Cardiology, Guangdong General Hospital, Guangzhou,
25
26 Guangdong Province, China
- 27
28
29 13. Department of Cardiology, Hainan General Hospital, Haikou, Hainan Province,
30
31 China
- 32
33
34 14. Department of Cardiology, The First Affiliated Hospital of Xinjiang Medical
35
36 University, Urumchi, The Xinjiang Uygur Autonomous Region, China
- 37
38
39 15. Department of Cardiology, Inner Mongolia People's Hospital, Hohhot, The Inner
40
41 Mongolia Autonomous Region, China
- 42
43
44 16. Department of Cardiology, Chinese PLA General Hospital, Beijing, China
- 45
46
47 17. Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical
48
49 Sciences, Beijing, China
- 50
51
52 18. Department of Cardiology, Guangzhou General Hospital of Guangzhou Military
53
54 Region, Guangzhou, Guangdong Province, China
- 55
56
57 19. Department of Cardiology, Shanghai Chest Hospital, Shanghai, China
- 58
59
60

1
2
3
4 20. Lumen Foundation, Miami, USA
5

6 21. Stent - Save A Life!, Paris, France
7
8

9 22. Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai,
10
11 China
12
13

14
15
16
17 **Running title:** Protocol of China STEMI Care Project
18

19
20
21
22 **Corresponding author:** Yong Huo, MD
23

24 Department of Cardiology, Peking University First Hospital
25

26
27 8 Xishiku St, Xicheng District, Beijing 100034, China
28

29
30 Email: huoyong@263.net.cn
31

32
33 Phone: 86-10-83572283
34

35
36 Fax: 86-10-66137748
37
38
39

40 **Date:**
41

42
43 This study was initiated in 2011 and will be completed in 2021. Phase 1 (CSCAP-1) is
44
45 conducted from 2011 to 2013, Phase 2 (CSCAP-2) is conducted from 2015 to 2018,
46
47 and Phase 3 (CSCAP-3) is conducted from 2018 to 2021, respectively.
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Successful ST-segment elevation myocardial infarction (STEMI) management is time-sensitive and is based on prompt reperfusion mainly to reduce patient mortality. It has evolved from a single hospital care to an integrated regional network approach over the last decades. This prospective study, named the China STEMI Care Project (CSCAP), aims to show how implementation of different types of integrated regional STEMI care networks can improve the reperfusion treatment rate, shorten the total duration of myocardial ischemia, and lead to mortality reduction step by step.

Methods and analysis: The CSCAP is a prospective, multicenter registry involving 3 phases. A total of 18 provinces, 4 municipalities and 2 autonomous regions in China were included. Patients who met with the third universal definition of myocardial infarction and the Chinese STEMI diagnosis and treatment guidelines were enrolled. Phase 1 (CSCAP-1) focused on the in-hospital process optimization of primary percutaneous coronary intervention (PPCI) hospitals, phase 2 (CSCAP-2) focused on the PPCI hospital-based regional STEMI care network construction together with emergency medical services and adjacent non-PPCI hospitals, and phase 3 (CSCAP-3) focused on the whole-city STEMI care network construction by promoting chest pain center accreditation. Systematic data collection, key performance index assessment and subsequent improvement were implemented throughout the project to continuously improve the quality of STEMI care.

Ethics and dissemination: The study has been reviewed and approved by the Ethics

1
2
3
4 Committee of Peking University First Hospital. Ranking reports of quality of care will
5
6 be generated available to all participant affiliations. Results will be disseminated via
7
8 peer-reviewed scientific journals and presentations at congresses.
9
10

11 **Trial registration number:** NCT03821012
12
13

14 15 16 **Strengths and limitations of this study** 17

- 18
19
20 ➤ CSCAP is the first project focused on establishing an integrated regional STEMI
21
22 care network in China through in-hospital process optimization, PPCI
23
24 hospital-based regional STEMI care network construction and whole-city STEMI
25
26 care network construction step by step, which will help to understand the
27
28 situations extensively and then improve accordingly.
29
30
31
32 ➤ Evaluation, feedback and improvement system will be established, aiming to
33
34 provide a tailored and continuous quality of care improvement plan based on the
35
36 conditions of different regions to further integrate the STEMI care network
37
38 nationwide.
39
40
41
42 ➤ Hospitals are not randomly selected in CSCAP which might be lead to the lack of
43
44 representatives to some degree. However, these hospitals are at a high level in
45
46 their region which is suitable to be core centers for regional network construction.
47
48 Their experiences could be valuable for hospitals in the same region but outside
49
50 this study.
51
52
53
54
55
56
57
58
59
60

Introduction

The burden of cardiovascular diseases is increasing and posing a major public health issue worldwide. The number of new onset of myocardial infarction will be tremendous in China in the next 15 years with the increasing risk factors and aging population [1]. The Chinese cardiovascular report in 2017 showed an increase in both the percentage of hospitalization and mortality of acute myocardial infarction (AMI) over the years. The trends of fast growth nationwide as well as higher in rural areas in AMI mortality were observed since 2005 and 2013, respectively [2].

ST-elevation myocardial infarction (STEMI), mainly caused by a sudden obstruction of the coronary artery with thrombus, benefits from both increasing reperfusion rate and shortening of the duration from the symptom occurrence to the opening of the target vessel [3 4]. Although implementing an evidence-based medicine significantly improves the prognosis of patients with STEMI, the gap of the translational application is still large in real-world settings [5]. A majority of Chinese STEMI patients miss the optimal treatment timing due to restrictions from both patients and medical services [6 7]. Additionally, the ratio of significant deficiency in STEMI reperfusion treatment remained at the level of around 55% in the last decade. Hence, the in-hospital mortality has not changed significantly yet [7].

Successful treatment of STEMI is a systemic issue, and the solution is neither a novel thrombolytic drug nor an intervention device. It can be brought about by comprehensive factors, including patient health awareness, physician level, physician–patient relationship, medical reimbursement system, prehospital emergency

1
2
3
4 system, in-hospital treatment, connection mechanism between prehospital and
5
6 in-hospital care, and posthospital management. Experiences from both the American
7
8 Lifeline program and the European Stent – Save a Life can be used for reference. The
9
10 quality of medical service can be significantly improved by establishing a regional
11
12 STEMI care network through close collaboration with different levels of hospitals and
13
14 the emergency medical system (EMS) [8 9].
15
16
17
18

19
20 Although large-scale studies have been conducted in China, such as Clinical
21
22 Pathways for Acute Coronary Syndromes in China (CPACS) focusing on the ACS
23
24 clinical pathway, Cardiovascular Disease in China (CCC) focusing on the in-hospital
25
26 treatment of acute coronary syndrome (ACS), China Acute Myocardial Infarction
27
28 (CAMI) Registry focusing on the management of both STEMI and non-STEMI, and
29
30 China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study
31
32 of Acute Myocardial Infarction (China PEACE-Retrospective AMI Study), none of
33
34 them focused on establishing a regional STEMI care network [7 10-12]. Serial
35
36 documents issued by the National Health Commission of China provide favorable
37
38 government support and further emphasize the importance of administrative
39
40 departments of health care at all levels in strengthening the construction of regional
41
42 emergency medical treatment system [13-15].
43
44
45
46
47
48
49

50
51 China has gradually increased the input of medical expense in the last few decades.
52
53 However, there are several types of medical insurances with different reimbursement
54
55 rate in China. The impacts of medical insurance policy coverage as well as
56
57 geographical and humanistic factors on STEMI management need to be discussed.
58
59
60

Objectives

The 10-year project, named as China STEMI Care Project (CSCAP), aims to show how implementation of different types of integrated regional STEMI care networks can improve the reperfusion treatment rate, shorten the total duration of myocardial ischemia, and lead to mortality reduction step by step. It will also provide useful information when building up a STEMI care network in other similar regions. In details, CSCAP focuses on improving the awareness of health and emergency treatment for STEMI patients, increasing the ratio of reperfusion treatment, shortening the overall duration of myocardial ischemia, and implementing standard secondary prevention to improve the long-term prognosis by establishing and optimizing medical care evaluation, feedback and improvement system with data support.

Methods and analysis

Study design

CSCAP is a prospective multicenter registry containing 3 phases. Phase 1 of CSCAP (CSCAP-1) focused on the in-hospital process optimization of primary percutaneous coronary intervention (PPCI) hospitals. Phase 2 of CSCAP (CSCAP-2) focused on the PPCI hospital-based regional STEMI care network construction with their adjacent non-PPCI hospitals and EMS. Phase 3 of CSCAP (CSCAP-3) focused on the whole-city STEMI care network construction by promoting chest pain center (CPC) accreditation (Fig. 1). Systematic data collection, assessment of quality of care and subsequent improvement were implemented throughout this study to continuously

1
2
3
4 improve the quality of care.
5

6 **Organizational framework**

7
8
9 CSCAP was established by the Chinese Medical Doctor Association and supported by
10
11 the National Health Commission of China in 2011. After collaborating with the
12
13 European Stent – Save a Life in CSCAP-3, China became its member country in 2017.
14
15 The project office, executive committee and steering committee were set up for the
16
17 purpose of management, implementation and academic support. Data management
18
19 and statistical analyses were conducted by the School of Public Health of Peking
20
21 University.
22
23
24
25

26 **Site selection**

27
28
29 CSCAP included 18 provinces (Anhui, Fujian, Gansu, Guangdong, Guangxi, Hainan,
30
31 Hebei, Heilongjiang, Henan, Hubei, Jiangsu, Liaoning, Shandong, Shanxi, Shaanxi,
32
33 Sichuan, Yunnan, and Zhejiang), 4 municipalities (Beijing, Chongqing, Shanghai, and
34
35 Tianjin) and 2 autonomous regions (Inner Mongolia and Xinjiang) in China when
36
37 considering incidence of STEMI, logistic as well as economic issues (Fig. 2).
38
39
40
41

42
43 A total of 53 tertiary hospitals qualified for PPCI in 14 provinces, municipalities or
44
45 autonomous regions of China were enrolled in CSCAP-1. The qualification of these
46
47 selected hospitals is based on the numbers of PCI cases and cardiovascular
48
49 interventionists extracted from the national PCI registry database. Moreover, all of
50
51 them are able to provide 24/7 PPCI service. These hospitals were selected because
52
53 they were at the top level in their city and potentially a hub for regional network
54
55 construction in CSCAP-2. A total of 244 PCI hospitals with adjunct non-PCI hospitals
56
57
58
59
60

1
2
3
4 from 24 provinces, municipalities and autonomous regions were selected to build up
5
6 the regional STEMI care network in CSCAP-2. A total of 7 cities (Harbin, Hangzhou,
7
8 Nanning, Qingdao, Shenzhen, Suzhou, and Taiyuan) from 7 provinces with different
9
10 EMS types were selected to build up the whole-city STEMI care network in
11
12 CSCAP-3 (Fig. 2).
13
14
15

16 17 **Patient enrollment**

18
19 Patients who met with the third universal definition of myocardial infarction and the
20
21 Chinese STEMI diagnosis and treatment guidelines were enrolled [16 17]. STEMI
22
23 patients with late admission to hospitals were also considered for the purpose of
24
25 exploring optimal methods to shorten total ischemic time containing both patient
26
27 delay and system delay issues. All patients received routine clinical assessments and
28
29 treatments without any experimental intervention. The updated guideline-directed
30
31 management such as reperfusion, auxiliary device implementation, elective
32
33 revascularization, medications and therapeutic lifestyle change will be implemented
34
35 during the whole study period.
36
37
38
39
40
41
42

43 In CSCAP-1, a total of 4,191 hospitalized patients, with symptom onset within 12 h
44
45 regardless of whether receiving reperfusion or symptom onset within 12–24 h of
46
47 needing PPCI, were enrolled consecutively in 2012. In CSCAP-2, a total of 20,799
48
49 patients with STEMI occurrence within 30 days regardless of reperfusion were
50
51 enrolled consecutively from PPCI hospitals 3 times at a 6-month interval from 2015
52
53 to 2017. In CSCAP-3, a total of 30 hospitalized STEMI patients with symptom onset
54
55 within 30 days will be enrolled consecutively from both PCI and non-PCI hospitals in
56
57
58
59
60

1
2
3
4 the whole-city network every 3 months. Those patients who survived after hospital
5
6 discharge will be followed up for 1 year.
7

8 9 **Regional network construction**

10
11 An integrated regional network contains PCI hospitals, non-PCI hospitals and EMS.
12
13 There are 3 major types of EMS exist in China: (1) independent-type EMS, which has
14
15 its own ambulances; (2) command-type EMS, which does not have its own
16
17 ambulances and uses local hospital ambulances; and (3) affiliate-type EMS, which is
18
19 based in hospitals and uses its ambulances. On the basis of these comprehensive
20
21 situations, patients may not be transported to optimal hospitals to receive effective
22
23 treatment in the shortest period because of incomplete communication [18]. Thus,
24
25 prehospital information transmission should be considered accordingly for hospital
26
27 alert and rapid and accurate transfer.
28
29
30
31
32
33

34
35 Although PPCI is the most effective treatment for STEMI, it is difficult to be
36
37 implemented in most of the primary hospitals, as they are limited by medical
38
39 condition, geographic location and techniques. Early thrombolysis and/or transfer PCI
40
41 strategy are the priority in most of these hospitals. Therefore, rapid identification of
42
43 STEMI and referral to a hospital with PPCI ability are extremely important
44
45 components in establishing a regional STEMI care network in China.
46
47
48
49

50
51 Optimizing the in-hospital green channel can significantly shorten the
52
53 door-to-balloon (D2B) time and door-to-needle (D2N) time while establishing a CPC
54
55 to integrate multiple resources is one of the most important methods [19 20].
56
57 Traditional CPC focuses on the optimization and integration of the in-hospital sources
58
59
60

1
2
3
4 aimed to shorten the process. The medical system and patient factors together
5
6 determine the delay in STEMI emergency treatment [21]. The concept of a modern
7
8 CPC expands to establish an effective regional network aiming to shorten the total
9
10 ischemia duration, thereby maximizing the advantage of reperfusion therapy. The
11
12 CPC independent accreditation in China was initiated in 2013 and 2 types
13
14 accreditation standards were developed according to PPCI ability [22 23].
15
16
17
18

19 **Procedures**

20
21
22 The treatment process of the patients suffered STEMI was based on the STEMI
23
24 protocol in the Announcement of Improving Medical Emergency Treatment
25
26 Performance of Acute Cardiovascular and Cerebrovascular Diseases issued by the
27
28 National Health Commission of China in 2015 [15]. Briefly, this flow chart included
29
30 1 center (EMS), 2 types of hospitals (PCI and non-PCI), 3 types of transfer methods
31
32 [EMS transfer to hospital, bypass emergency department (ED) and inter-hospital
33
34 transfer], and 11 clinical pathways. Different clinical pathways were selected to
35
36 execute the optimal emergency treatment based on the visiting time, approaching
37
38 method and hospital ability (Fig. 3). In addition, the procedures should be launched
39
40 without results of myocardial biomarkers according to typical ischemic symptoms and
41
42 electrocardiogram (ECG).
43
44
45
46
47
48
49

50 **Data collection and management**

51
52
53 Data of all treatment process were collected, including patient general information,
54
55 prehospital treatment, in-hospital management and follow-up management (Table 1).
56
57
58 Considering the real situation in ED, many time points could not be recorded
59
60

1
2
3
4 manually on time which might lead to missing and inaccurate data. Mobile device app
5
6 could record these time variables through a simple click and complete the prehospital
7
8 ECG transmission. The technique of data auto-capture becomes
9
10 more and more popular at present and should resolve this issue. All of these methods
11
12 are considered gradually in this study.
13
14
15

16
17 Data were inputted into a self-built electronic database together with two existing
18
19 databases of both CPC accreditation and national PCI registry by trained clinical
20
21 research coordinators and clinicians in each hospital. The quality of the data was
22
23 monitored and suspicious contents with missing, outlier and logical errors were
24
25 reviewed mainly. When all problems are resolved, the database is then locked for
26
27 statistical analysis.
28
29
30
31

32
33 The describing method was used in CSCAP to mainly rank data quality and
34
35 medical quality. Continuous variables were described as mean (standard deviation) or
36
37 median (interquartile range), while categorical variables were described as a
38
39 percentage. The multivariate regression model was used to evaluate the factors related
40
41 to the assessment of medical quality. The Cox model was used to analyze the
42
43 association between exposures and medical outcomes. A *P* value < 0.05 was defined
44
45 as a significant difference. All analyses were performed using R
46
47 (<http://www.R-project.org>).
48
49
50
51

52 53 **Key performance index**

54
55 The National Cardiovascular Data Registry (NCDR), established since 1997, has
56
57 become the basis for project implementation and quality evaluation as well as
58
59
60

1
2
3
4 research center medical quality improvement in the United States. It has a positive
5
6 impact on clinical practice, medical payment, clinical research and government
7
8 decision-making [24 25]. The present study referred to the NCDR model to optimize
9
10 the STEMI quality of care and established an evaluation, feedback and improvement
11
12 system for primary key performance indexes (KPIs). For KPI selection, PPCI
13
14 hospitals focused on the improvement in the PPCI capacity and efficiency, non-PPCI
15
16 hospitals focused on the improvement in rapid diagnosis, thrombolysis and referral
17
18 capacity to PPCI hospitals, and EMS focused on the improvement in information
19
20 transmission to alert hospitals early for the purpose of rapid and accurate transfer.
21
22
23
24
25

26
27 A total of 13 primary KPIs were selected for medical quality evaluation based on
28
29 different roles of EMS and hospitals in STEMI management (Table 2). These KPIs
30
31 are different in each phase but have internal logic. Except reperfusion rate, method
32
33 and cardiovascular outcomes, different treatment delay indexes are selected in
34
35 different phases which will shift to others step by step according to the progress of
36
37 network construction. D2N and D2B time, defined as from in-hospital FMC to target
38
39 vessel open, were used to evaluate in-hospital delay in CSCAP-1. First medical
40
41 contact-to-balloon time (FMC2B) and first medical contact-to-needle time (FMC2N)
42
43 time, defined as FMC by emergency system or hospital to target vessel open, were
44
45 used to evaluate the whole medical system delay in CSCAP-2. Total ischemic time,
46
47 defined as from symptom onset to target vessel open, is used in CSCAP-3 to add the
48
49 information of patient delay.
50
51
52
53
54
55
56

57
58 The circular enrollment–evaluation–feedback–improvement method will be
59
60

1
2
3
4 implemented in both CSCAP-2 and CSCAP-3. The quality feedback report contains
5
6 each KPI of the affiliation and its ranking within its regional network and among all
7
8 affiliations. Comparison of KPIs with itself and those of others was analyzed for
9
10 tailed improvements.
11
12

13 14 15 **Patient and public involvement**

16
17
18 The development of the research questions and outcome measures was informed by
19
20 the current situations of lacking of the integrated regional STEMI care network in
21
22 China. Patients were not offered the opportunity to participate in the study design.
23
24 They will obtain the information related to the study via public media as well as
25
26 academic publications.
27
28
29
30
31
32

33 34 **Ethics and dissemination**

35
36 The study was conducted in accordance with Declaration of Helsinki. The study
37
38 protocol was approved by the Ethics Committee of Peking University First Hospital.
39
40 Ranking reports of quality of care will be made available to all participant affiliations.
41
42 Results will be disseminated at international conferences and published in
43
44 peer-reviewed scientific journals or public media.
45
46
47
48
49

50 51 **Discussion**

52
53 The integration and optimization of an integrated regional network with government
54
55 support are urgent issues of STEMI care especially in China. CSCAP is the first
56
57 prospective registry study focused on regional network construction and will help
58
59
60

1
2
3
4 extensively understand the basic situations and the differences with other countries,
5
6 which leading to optimized clinical practice and problem-guided improvement. It will
7
8
9 provide important information for the network construction shifting from the PPCI
10
11 hospital-centered regional network to the whole-city network step by step so as to
12
13
14 create an optimal integrate STEMI care system in China.
15
16
17
18

19 **Contributions** Yan Zhang coordinated the study, assisted with data collection,
20
21 performed data analysis, and drafted the manuscript. Bo Yu, Yaling Han, Jianan
22
23 Wang, Lixia Yang, Zheng Wan, Zheng Zhang, Yuguo Chen, Xianghua Fu, Chuanyu
24
25 Gao, Bao Li, Jiyan Chen, Ming Wu, Yitong Ma, Xingsheng Zhao, Yundai Chen,
26
27 Hongbing Yan, Dingcheng Xiang, Weiyi Fang, and Junbo Ge carried out the data
28
29 collection and helped draft the manuscript. Sameer Mehta and Christoph K Naber
30
31 participated in the design and helped draft the manuscript. Yong Huo, principal
32
33 investigator of the project, conceived and designed the project, helped collect data and
34
35 draft the manuscript. All authors reviewed the results and approved the final version
36
37
38
39
40
41
42
43
44
45
46
47
48 of the manuscript.
49

50 **Acknowledgments**

51 The authors thank the study team members and patient advisers of all
52
53 collaborative hospitals and emergency medical services. They are also grateful to the
54
55 organizational coordination of Chinese Medical Doctor Association and China
56
57 Cardiovascular Association. They acknowledge the supports provided by the National
58
59
60

1
2
3
4 Health Commission and local governments in China.
5
6
7
8

9 **Funding** CSCAP was funded by Sanofi-Aventis, Abbott, and AstraZeneca.
10

11 **Competing interest** None declared.
12

13 **Patient consent for publication** Not required.
14

15 **Ethics approval** This study was reviewed and approved by the Ethics Committees
16
17 at Peking University First Hospital.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Stevens W, Peneva D, Li JZ, et al. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. *BMC health services research* 2016;**16**:175.
2. *Report on cardiovascular disease in China*: Encyclopedia of China Publishing house, 2017.
3. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;**127**:e362-425.
4. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European heart journal* 2012;**33**:2569-619.
5. Eagle KA, Nallamothu BK, Mehta RH, et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. *European heart journal* 2008;**29**:609-17.
6. Song L, Hu DY, Yan HB, et al. Influence of ambulance use on early reperfusion therapies for acute myocardial infarction. *Chinese medical journal* 2008;**121**:771-5.

- 1
2
3
4 7. Li J, Li X, Wang Q, et al. ST-segment elevation myocardial infarction in China
5
6 from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial
7
8 Infarction Study): a retrospective analysis of hospital data. *Lancet*
9
10 2015;**385**:441-51.
11
12
- 13
14 8. Jollis JG, Granger CB, Henry TD, et al. Systems of care for ST-segment-elevation
15
16 myocardial infarction: a report From the American Heart Association's
17
18 Mission: Lifeline. *Circulation. Cardiovascular quality and outcomes*
19
20 2012;**5**:423-8.
21
22
- 23
24 9. Kristensen SD, Fajadet J, Di Mario C, et al. Implementation of primary angioplasty
25
26 in Europe: stent for life initiative progress report. *EuroIntervention : journal of*
27
28 *EuroPCR in collaboration with the Working Group on Interventional*
29
30 *Cardiology of the European Society of Cardiology* 2012;**8**:35-42.
31
32
- 33
34 10. Gao R, Patel A, Gao W, et al. Prospective observational study of acute coronary
35
36 syndromes in China: practice patterns and outcomes. *Heart* 2008;**94**:554-60.
37
38
- 39
40 11. Hao Y, Liu J, Liu J, et al. Rationale and design of the Improving Care for
41
42 Cardiovascular Disease in China (CCC) project: A national effort to prompt
43
44 quality enhancement for acute coronary syndrome. *American heart journal*
45
46 2016;**179**:107-15.
47
48
- 49
50 12. Xu H, Li W, Yang J, et al. The China Acute Myocardial Infarction (CAMI)
51
52 Registry: A national long-term registry-research-education integrated platform
53
54 for exploring acute myocardial infarction in China. *American heart journal*
55
56 2016;**175**:193-201.e3.
57
58
59
60

- 1
2
3
4 13. Pre-hospital medical emergency management measures. *Chinese Village Medicine*
5
6 2014;85-86. (In Chinese)
7
8
9 14. National Health Commission of China. Guiding Principles for Construction and
10
11 Management of Chest Pain Center (Trial). 2017. (In Chinese)
12
13
14 15. National Health Commission of China. The Announcement of Improving Medical
15
16 Emergency Treatment Performance of Acute Cardiovascular and
17
18 Cerebrovascular Diseases. 2015. (In Chinese)
19
20
21
22 16. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial
23
24 infarction. *Circulation* 2012;**126**:2020-35.
25
26
27 17. Chinese Society of Cardiology, Editorial board of Chinese Journal of Cardiology.
28
29 Guidelines for the diagnosis and treatment of acute ST segment elevation
30
31 myocardial infarction. *Chinese Journal of Cardiology* 2015;**43**:380-93. (In
32
33 Chinese)
34
35
36
37 18. Ranasinghe I, Rong Y, Du X, et al. System barriers to the evidence-based care of
38
39 acute coronary syndrome patients in China: qualitative analysis. *Circulation.*
40
41 *Cardiovascular quality and outcomes* 2014;**7**:209-16.
42
43
44
45 19. Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door-to-balloon
46
47 time in acute myocardial infarction. *The New England journal of medicine*
48
49 2006;**355**:2308-20.
50
51
52
53 20. Graff LG, Dallara J, Ross MA, et al. Impact on the care of the emergency
54
55 department chest pain patient from the chest pain evaluation registry
56
57 (CHEPER) study. *The American journal of cardiology* 1997;**80**:563-8.
58
59
60

- 1
2
3
4 21. Windecker S, Bax JJ, Myat A, et al. Future treatment strategies in ST-segment
5
6 elevation myocardial infarction. *Lancet* 2013;**382**:644-57.
7
8
9 22. China Chest Pain Center Accreditation Work Committee. Standard for Chinese
10
11 Chest Pain Center accreditation. *Chinese Journal of Interventional Cardiology*
12
13 2016;**24**:121-30. (In Chinese)
14
15
16 23. China Chest Pain Center Accreditation Work Committee. Standard for Chinese
17
18 Primary Chest Pain Center accreditation. *Chinese Journal of Interventional*
19
20 *Cardiology* 2016;**24**:131-33. (In Chinese)
21
22
23 24. Diercks DB, Kontos MC, Chen AY, et al. Utilization and impact of pre-hospital
24
25 electrocardiograms for patients with acute ST-segment elevation myocardial
26
27 infarction: data from the NCDR (National Cardiovascular Data Registry)
28
29 ACTION (Acute Coronary Treatment and Intervention Outcomes Network)
30
31 Registry. *Journal of the American College of Cardiology* 2009;**53**:161-6.
32
33
34 25. Krim SR, Vivo RP, Krim NR, et al. Regional differences in clinical profile,
35
36 quality of care, and outcomes among Hispanic patients hospitalized with acute
37
38 myocardial infarction in the Get with Guidelines-Coronary Artery Disease
39
40 (GWTG-CAD) registry. *American heart journal* 2011;**162**:988-95. e4.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. CSCAP data elements

Category	Example elements
Patient baseline information	Demographics (age, sex, ethnicity, occupation, marriage status, and medical insurance type) Risk factors (smoking status, BMI, hypertension, diabetes, dyslipidemia, peripheral artery disease, MI history, stroke history, and prior revascularization) Clinical presentation (blood pressure, heart rate, and cardiac function classification)
Prehospital information	Patient (symptoms, symptom onset time, and hospital approaching method) EMS (response time, transfer process, first ECG time, ECG transmission ratio, and bypass ED ratio) Non-PCI hospital (hospital approaching method, first medical contact time, admission time, first ECG time, diagnosis time, consent time, reperfusion and other treatment, DI-DO time, and transfer process)
PCI hospital information	Reperfusion (methods, indication and contraindication, and nonreperfusion reasons) Treatment delay (hospital approaching method, first medical contact time, bypass ED ratio, admission time, first ECG time, catheter lab ready time, consent time, D2B, D2N, FMC2B,

1
2
3
4 FMC2N, total ischemic time, and reasons of delay)
5
6
7 PCI procedures (operative route, coronary angiography
8
9 results, aspiration, culprit vessels, stent, and elective PCI)
10
11
12 Thrombolytic procedures (thrombolytic agent, dose, and
13
14 outcome)
15
16
17 Medications (loading dose DAPT and statin, antiplatelets,
18
19 β -blockers, statin, ACEI/ARB, GP IIb/IIIa inhibitor, and
20
21 anticoagulant with dose and contraindication information)
22
23
24 Laboratory results (troponin, CK-MB, creatinine, hemoglobin,
25
26 HbA1c, fasting glucose, BNP or NT-proBNP, lipid profiles,
27
28 ECG, and UCG)
29
30
31 Discharge (diagnosis, in-hospital duration, expense, and
32
33 medications)
34
35
36 Outcomes (death, non-fatal reinfarction, nonfatal stroke,
37
38 revascularization, mechanical complication, and bleeding)
39
40
41
42
43 Follow-up and management Presentation status (symptom, cardiac function classification,
44
45 blood pressure, heart rate, and follow-up on-time ratio)
46
47
48 Laboratory results (lipid profiles, glucose traits, HbA1c,
49
50 creatinine, hemoglobin, BNP or NT-proBNP, ECG, and
51
52 UCG)
53
54
55 Medications (antiplatelets, β -blockers, statin, and ACEI/ARB)
56
57
58 Risk factor control rate (Blood pressure, lipid, glucose, and
59
60

1
2
3
4 smoking cessation)

5
6 Outcomes (death, nonfatal reinfarction, stroke,
7
8 revascularization, rehospitalization due to unstable angina
9
10 pectoris, heart failure or other cardiovascular reasons, and
11
12 bleeding)
13
14
15

16
17 ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
18
19 BMI, body mass index; BNP, brain natriuretic peptide; CK-MB, creatine kinase MB
20
21 isoenzyme; DAPT, dual antiplatelet therapy; D2B, door to balloon; D2N, door to
22
23 needle; DI-DO, door in-door out; ECG, electrocardiograph; ED, emergency
24
25 department; EMS, emergency medical service; FMC2B, first medical contact to
26
27 balloon; FMC2N, first medical contact to needle injection; GP IIb/IIIa, glycoprotein
28
29 IIb/IIIa; HbA1c, glycosylated hemoglobin A1c; MI, myocardial infarction;
30
31 NT-ProBNP, N-terminal pro-brain natriuretic peptide; PCI, percutaneous coronary
32
33 intervention; UCG, ultrasound cardiogram.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Primary performance measures for evaluating medical care quality

Primary performance measures

Prehospital care

Symptom onset to arrival in hospital (min)

Hospital admission ratio via ambulance (%)

Prehospital ECG transmission ratio (%)

Bypass ED ratio in patients with symptom onset within 12 h (%)

Reperfusion

Overall reperfusion ratio (%)

Thrombolysis ratio in patients with symptom onset within 12 h (%)

Primary PCI ratio in patients with symptom onset within 12 h (%)

D2B in patients with symptom onset within 12 h (min)

D2N in patients with symptom onset within 12 h (min)

DischargeUsage of both DAPT, statin, β blocker, and ACEI/ARB in patients without contraindication (%)**Outcomes**

In-hospital mortality (%)

Follow-up and management

1-Year on-time follow-up ratio (%)

1-Year MACE (%), including mortality, non-fatal myocardial infarction, non-fatal stroke, and hospitalization due to heart failure or acute coronary syndrome

ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;

1
2
3
4 DAPT, dual antiplatelet therapy; D2B, door to balloon; D2N, door to needle; ECG,
5
6 electrocardiogram; ED, emergency department; PCI, percutaneous coronary
7
8
9 intervention; MACE, major adverse cardiovascular event.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **Figure legends**
5


6 Figure 1. CSCAP whole-city STEMI care network construction.
7

8
9 Figure 2. Geographic distribution of CSCAP.
10

11
12 Figure 3. CSCAP STEMI emergency care flow chart.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



170x102mm (300 x 300 DPI)



170x170mm (300 x 300 DPI)



PCI, percutaneous intervention

170x148mm (300 x 300 DPI)

BMJ Open

Protocol of the China ST-segment elevation myocardial infarction (STEMI) Care Project (CSCAP): a 10-year project to improve quality of care by building up a regional STEMI care network

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026362.R2
Article Type:	Protocol
Date Submitted by the Author:	25-Mar-2019
Complete List of Authors:	<p>Zhang, Yan; Peking University First Hospital, Department of Cardiology Yu, Bo; Key Laboratories of Education Ministry for Myocardial Ischemia Mechanism and Treatment, 2nd Affiliated Hospital of Harbin Medical University, Cardiology Han, YL; The General Hospital of Shenyang Military Region, Department of Cardiology Wang, Jianan; The Second Affiliated Hospital, Zhejiang University, Department of Cardiology Yang, Lixia; Kunming General Hospital of Chengdu Military Region, Department of Cardiology Wan, Zheng; The General Hospital of Tianjin Medical University, department of cardiology Zhang, Zheng; The First Hospital of Lanzhou University, department of cardiology Chen, Yu-guo; Qilu Hospital of Shandong University, Department of Emergency Fu, Xianghua; The Second Hospital of Hebei Medical University, Department of Cardiology Gao, Chuanyu; Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Cardiology Li, Bao; Shanxi Cardiovascular Hospital, department of cardiology Chen, Ji-yan; Guangdong Cardiovascular Institute, Guangdong provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Cardiology Wu, Ming; Hainan General Hospital, Department of cardiology Ma, Yitong; The First Affiliated Hospital of Xinjiang Medical University, department of cardiology Zhao, Xingsheng; Inner Mongolia People's Hospital, department of cardiology Chen, Yundai; Chinese PLA General Hospital, department of cardiology Yan, Hongbing; Fuwai Hospital, Chinese Academy of Medical Sciences, department of cardiology Xiang, Dingcheng; Guangzhou General Hospital of Guangzhou Military Region, Department of Cardiology Fang, Weiyi; Shanghai Chest Hospital, department of cardiology Mehta, Sameer; Lumen Foundation Naber, Christoph K; Stent Save a Life Ge, Junbo; Zhongshan Hospital Fudan University, department of</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	cardiology Huo, Yong ; Peking University First Hospital,
Primary Subject Heading :	Evidence based practice
Secondary Subject Heading:	Medical management
Keywords:	Accreditation, chest pain center, network, reperfusion, ST-elevation myocardial infarction

SCHOLARONE™
Manuscripts

1
2
3
4 **Protocol of the China ST-segment elevation myocardial infarction (STEMI) Care**
5
6 **Project (CSCAP): a 10-year project to improve quality of care by building up a**
7
8 **regional STEMI care network**
9
10

11
12
13
14 Yan Zhang¹, Bo Yu², Yaling Han³, Jianan Wang⁴, Lixia Yang⁵, Zheng Wan⁶, Zheng
15
16 Zhang⁷, Yuguo Chen⁸, Xianghua Fu⁹, Chuanyu Gao¹⁰, Bao Li¹¹, Jiyan Chen¹², Ming
17
18 Wu¹³, Yitong Ma¹⁴, Xingsheng Zhao¹⁵, Yundai Chen¹⁶, Hongbing Yan¹⁷, Dingcheng
19
20 Xiang¹⁸, Weiyi Fang¹⁹, Sameer Mehta²⁰, Christoph K. Naber²¹, Junbo Ge²², *Yong
21
22 Huo¹, on behalf of China STEMI Care Project (CSCAP) Investigators
23
24
25
26
27
28
29

- 30 1. Department of Cardiology, Peking University First Hospital, Beijing, China
31
32 2. Department of Cardiology, The Second Affiliated Hospital of Harbin Medical
33
34 University, Harbin, Heilongjiang Province, China
35
36 3. Department of Cardiology, The General Hospital of Shenyang Military Region,
37
38 Shenyang, Liaoning Province, China
39
40 4. Department of Cardiology, The Second Affiliated Hospital Zhejiang University
41
42 School of Medicine, Hangzhou, Zhejiang Province, China
43
44 5. Department of Cardiology, Kunming General Hospital of Chengdu Military
45
46 Region, Kunming, Yunnan Department of Cardiology, China
47
48 6. Department of Cardiology, Tianjin Medical University General Hospital, Tianjin,
49
50 China
51
52 7. Department of Cardiology, The First Hospital of Lanzhou University, Lanzhou,
53
54
55
56
57
58
59
60

1
2
3
4 Gansu Province, China
5

6
7 8. Department of Emergency, Qilu Hospital of Shandong University, Jinan,
8
9 Shandong Province, China
10

11
12 9. Department of Cardiology, The Second Hospital of Hebei Medical University,
13
14 Shijiazhuang, Hebei Province, China
15

16
17 10. Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou,
18
19 Henan Province, China
20

21
22 11. Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi
23
24 Province, China
25

26
27 12. Department of Cardiology, Guangdong General Hospital, Guangzhou,
28
29 Guangdong Province, China
30

31
32 13. Department of Cardiology, Hainan General Hospital, Haikou, Hainan Province,
33
34 China
35

36
37 14. Department of Cardiology, The First Affiliated Hospital of Xinjiang Medical
38
39 University, Urumchi, The Xinjiang Uygur Autonomous Region, China
40

41
42 15. Department of Cardiology, Inner Mongolia People's Hospital, Hohhot, The Inner
43
44 Mongolia Autonomous Region, China
45

46
47 16. Department of Cardiology, Chinese PLA General Hospital, Beijing, China
48

49
50 17. Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical
51
52 Sciences, Beijing, China
53

54
55 18. Department of Cardiology, Guangzhou General Hospital of Guangzhou Military
56
57 Region, Guangzhou, Guangdong Province, China
58
59
60

- 1
2
3
4 19. Department of Cardiology, Shanghai Chest Hospital, Shanghai, China
5
6
7 20. Lumen Foundation, Miami, USA
8
9
10
11
12 22. Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai,
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- China

Running title: Protocol of China STEMI Care Project

Corresponding author: Yong Huo, MD

Department of Cardiology, Peking University First Hospital

8 Xishiku St, Xicheng District, Beijing 100034, China

Email: huoyong@263.net.cn

Phone: 86-10-83572283

Fax: 86-10-66137748

Date:

This study was initiated in 2011 and will be completed in 2021. Phase 1 (CSCAP-1) is conducted from 2011 to 2013, Phase 2 (CSCAP-2) is conducted from 2015 to 2018, and Phase 3 (CSCAP-3) is conducted from 2018 to 2021, respectively.

Abstract

Introduction: Successful ST-segment elevation myocardial infarction (STEMI) management is time-sensitive and is based on prompt reperfusion mainly to reduce patient mortality. It has evolved from a single hospital care to an integrated regional network approach over the last decades. This prospective study, named the China STEMI Care Project (CSCAP), aims to show how implementation of different types of integrated regional STEMI care networks can improve the reperfusion treatment rate, shorten the total duration of myocardial ischemia, and lead to mortality reduction step by step.

Methods and analysis: The CSCAP is a prospective, multicenter registry study of 3 phases. A total of 18 provinces, 4 municipalities and 2 autonomous regions in China were included. Patients who meet the third universal definition of myocardial infarction and the Chinese STEMI diagnosis and treatment guidelines are enrolled. Phase 1 (CSCAP-1) focuses on the in-hospital process optimization of primary percutaneous coronary intervention (PPCI) hospitals, phase 2 (CSCAP-2) focuses on the PPCI hospital-based regional STEMI care network construction together with emergency medical services and adjacent non-PPCI hospitals, while phase 3 (CSCAP-3) focuses on the whole-city STEMI care network construction by promoting chest pain center accreditation. Systematic data collection, key performance index assessment and subsequent improvement are implemented throughout the project to continuously improve the quality of STEMI care.

Ethics and dissemination: The study has been reviewed and approved by the Ethics

1
2
3
4 Committee of Peking University First Hospital. Ranking reports of quality of care will
5
6 be generated available to all participant affiliations. Results will be disseminated via
7
8 peer-reviewed scientific journals and presentations at congresses.
9
10

11 **Trial registration number:** NCT03821012
12
13

14 15 16 **Strengths and limitations of this study** 17

- 18
19 ➤ CSCAP is the first project focuses on establishing an integrated regional STEMI
20
21 care network in China through in-hospital process optimization, PPCI
22
23 hospital-based regional STEMI care network construction and whole-city STEMI
24
25 care network construction step by step, which will help us to understand the
26
27 situations extensively and then improve accordingly.
28
29
- 30
31 ➤ Evaluation, feedback and improvement system will be established, aiming to
32
33 provide a tailored and continuous quality of care improvement plan based on the
34
35 conditions of different regions to further integrate the STEMI care network
36
37 nationwide.
38
39
- 40
41 ➤ Hospitals are not randomly selected in CSCAP which might be lead to lack of
42
43 representatives to some degree. However, these hospitals are at a high level in
44
45 their region which is suitable to be core centers for regional network construction.
46
47 Their experiences could be valuable for hospitals in the same region but not in
48
49 this study.
50
51
52
53
54
55
56
57
58
59
60

Introduction

The burden of cardiovascular diseases is increasing and posing a major public health issue worldwide. The number of new onset of myocardial infarction will be tremendous in China in the next 15 years with the increasing risk factors and aging population [1]. The Chinese cardiovascular report in 2017 has shown an increase in both the percentage of hospitalization and mortality of acute myocardial infarction (AMI) over the years. The trends of fast growth nationwide as well as higher AMI mortality in rural areas in were observed since 2005 and 2013, respectively [2].

ST-elevation myocardial infarction (STEMI), mainly caused by a sudden obstruction of the coronary artery with thrombus, benefits from both increasing reperfusion rate and shortening of the duration from the symptom occurrence to the opening of the target vessel [3 4]. Although implementing an evidence-based medicine significantly improves the prognosis of patients with STEMI, the gap of clinical application is still large in real-world settings [5]. A majority of Chinese STEMI patients miss the optimal treatment timing due to restrictions from both patients and medical services [6 7]. Additionally, the ratio of STEMI reperfusion treatment remained at the level of around 55% in the last decade. Hence, the in-hospital mortality has not changed significantly yet [7].

Successful treatment of STEMI is a systemic issue, and the solution is neither a novel thrombolytic drug nor an intervention device. It can be brought about by comprehensive factors, including the patients' health awareness, physician's skill, physician-patient's relationship, medical reimbursement system, prehospital

1
2
3
4 emergency medical system (EMS), in-hospital treatment, connection mechanism
5
6 between prehospital and in-hospital care, and posthospital management. Experiences
7
8 from both the American Lifeline program and the European Stent – Save a Life can
9
10 be used for reference. The quality of medical care can be significantly improved by
11
12 establishing a regional STEMI care network through close collaboration between
13
14 hospitals of different levels and EMS [8 9].
15
16
17
18

19
20 Although large-scale studies have been conducted in China, such as Clinical
21
22 Pathways for Acute Coronary Syndromes in China (CPACS) focusing on the ACS
23
24 clinical pathway, Cardiovascular Disease in China (CCC) focusing on the in-hospital
25
26 treatment of acute coronary syndrome (ACS), China Acute Myocardial Infarction
27
28 (CAMI) Registry focusing on the management of both STEMI and non-STEMI, and
29
30 China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study
31
32 of Acute Myocardial Infarction (China PEACE-Retrospective AMI Study), none of
33
34 them focused on establishing a regional STEMI care network [7 10-12]. Serial
35
36 documents issued by the National Health Commission of China provide favorable
37
38 government supports and further emphasize the important rolls of administrative
39
40 departments of health care at all levels in strengthening the construction of regional
41
42 emergency care network [13-15].
43
44
45
46
47
48
49

50
51 China has gradually increased the input of medical expense in the last few decades.
52
53 However, there are several types of medical insurances with different reimbursement
54
55 policy in China. The impacts of health economic factors as well as geographical and
56
57 humanistic factors on quality of STEMI care need to be discussed either.
58
59
60

Objectives

The 10-year project, named as China STEMI Care Project (CSCAP), aims to show how implementation of different types of integrated regional STEMI care networks can improve the reperfusion treatment rate, shorten the total duration of myocardial ischemia, and lead to mortality reduction step by step. It will also provide useful information when building up a STEMI care network in other similar regions. In details, CSCAP focuses on improving the awareness of health and emergency treatment for STEMI patients, increasing the ratio of reperfusion treatment, shortening the overall duration of myocardial ischemia, and implementing standard secondary prevention to improve the long-term prognosis by establishing and optimizing medical care evaluation, feedback and improvement system with data support.

Methods and analysis

Study design

CSCAP is a prospective multicenter registry containing 3 phases. Phase 1 of CSCAP (CSCAP-1) focuses on the in-hospital process optimization of primary percutaneous coronary intervention (PPCI) hospitals. Phase 2 of CSCAP (CSCAP-2) focuses on the PPCI hospital-based regional STEMI care network construction with their adjacent non-PPCI hospitals and EMS. Phase 3 of CSCAP (CSCAP-3) focuses on the whole-city STEMI care network construction by promoting chest pain center (CPC) accreditation (Fig. 1). Systematic data collection, assessment of quality of care and subsequent improvement are implemented throughout this study to continuously

1
2
3
4 improve the quality of care.
5

6 **Organizational framework**

7
8
9 CSCAP was established by the Chinese Medical Doctor Association and supported by
10
11 the National Health Commission of China in 2011. After collaborating with the
12
13 European Stent – Save a Life in CSCAP-3, China became its member country in 2017.
14
15 The project office, executive committee and steering committee were set up for the
16
17 purposes of management, implementation and academic support. Data management
18
19 and statistical analyses were conducted by the School of Public Health of Peking
20
21 University.
22
23
24
25

26 **Site selection**

27
28
29 CSCAP included 18 provinces (Anhui, Fujian, Gansu, Guangdong, Guangxi, Hainan,
30
31 Hebei, Heilongjiang, Henan, Hubei, Jiangsu, Liaoning, Shandong, Shanxi, Shaanxi?,
32
33 Sichuan, Yunnan, and Zhejiang), 4 municipalities (Beijing, Chongqing, Shanghai, and
34
35 Tianjin) and 2 autonomous regions (Inner Mongolia and Xinjiang) in China when
36
37 considering incidence of STEMI, logistic as well as economic issues.
38
39
40
41

42
43 A total of 53 tertiary hospitals qualified for PPCI in 10 provinces, 2 municipalities
44
45 and 2 autonomous regions of China were enrolled in CSCAP-1. The qualification of
46
47 these selected hospitals was based on the numbers of PCI cases and cardiovascular
48
49 interventionists extracted from the national PCI registry database. Moreover, all of
50
51 them are able to provide 24/7 PPCI service. These hospitals were selected because
52
53 they were at the top level in their city and potentially a hub for regional network
54
55 construction in CSCAP-2. A total of 244 PCI hospitals with adjunct non-PCI hospitals
56
57
58
59
60

1
2
3
4 from 18 provinces, 4 municipalities and 2 autonomous regions were selected to build
5
6 up the regional STEMI care network in CSCAP-2. A total of 7 cities (Harbin,
7
8 Hangzhou, Nanning, Qingdao, Shenzhen, Suzhou, and Taiyuan) from 6 provinces and
9
10 1 autonomous region with different EMS types were selected to build up the
11
12 whole-city STEMI care network in CSCAP-3.
13
14
15

16 **Patient enrollment**

17
18 Patients who met with the third universal definition of myocardial infarction and the
19
20 Chinese STEMI diagnosis and treatment guidelines were enrolled [16 17]. STEMI
21
22 patients with late admission to hospitals were also considered for the purpose of
23
24 exploring optimal methods to shorten total ischemic time causing by both patient and
25
26 system delay. All patients received routine clinical assessments and treatments
27
28 without any experimental intervention. The updated guideline-directed management
29
30 such as reperfusion, auxiliary device implementation, elective revascularization,
31
32 medications and therapeutic lifestyle change will be implemented during the whole
33
34 study period.
35
36
37
38
39
40
41
42

43 In CSCAP-1, a total of 4,191 hospitalized patients, with symptom onset within 12 h
44
45 regardless of whether receiving reperfusion or symptom onset within 12–24 h but still
46
47 need PPCI, were enrolled consecutively in 2012. In CSCAP-2, a total of 20,799
48
49 patients with STEMI occurrence within 30 days regardless of reperfusion were
50
51 enrolled consecutively from PPCI hospitals 3 times at a 6-month interval from 2015
52
53 to 2017. In CSCAP-3, a total of 30 hospitalized STEMI patients with symptom onset
54
55 within 30 days will be enrolled consecutively from both PCI and non-PCI hospitals in
56
57
58
59
60

1
2
3
4 the whole-city network every 3 months. Those patients who survived after hospital
5
6 discharge will be followed up for 1 year.
7

8 9 **Regional network construction**

10
11 An integrated regional network contains PCI hospitals, non-PCI hospitals and EMS.
12
13 There are 3 major types of EMS in China: (1) independent EMS, which has its own
14
15 ambulances; (2) commanding EMS, which does not have its own ambulances and
16
17 uses hospital ambulances; and (3) affiliated EMS, which is based in hospitals and uses
18
19 their ambulances. Due to these comprehensive situations, patients may not be
20
21 transported to optimal hospitals to receive effective treatment in the shortest period
22
23 because of incomplete communication [18]. Thus, prehospital information
24
25 transmission should be considered accordingly for hospital alert and rapid and
26
27 accurate transfer.
28
29
30
31
32
33

34
35 Although PPCI is the most effective treatment for STEMI, it is difficult to be
36
37 implemented in most of the primary hospitals, as they are limited by medical
38
39 condition, geographic location and techniques. Early thrombolysis and/or transfer PCI
40
41 strategy are the priority in these hospitals. Therefore, rapid identification of STEMI
42
43 and referral to a hospital with PPCI ability are extremely important components in
44
45 establishing a regional STEMI care network in China.
46
47
48
49

50
51 Optimizing the in-hospital green channel can significantly shorten the
52
53 door-to-balloon (D2B) time and door-to-needle (D2N) time, while establishing a CPC
54
55 to integrate multiple resources is one of the most important methods [19 20].
56
57 Traditional CPC focuses on the optimization and integration of the in-hospital sources
58
59
60

1
2
3
4 aiming to shorten the time of the process. The medical system and patient factors
5
6 together determine the delay in STEMI emergency treatment [21]. The concept of a
7
8 modern CPC expands to establishing an effective regional network aiming to shorten
9
10 the total ischemia duration, thereby maximizing the advantage of reperfusion therapy.
11
12 The CPC independent accreditation in China was initiated in 2013 and 2 types
13
14 accreditation standards were developed according to PPCI ability [22 23].
15
16
17
18

19 **Procedures**

20
21
22 The treatment process of patients suffered STEMI was based on the STEMI protocol
23
24 in the Announcement of Improving Medical Emergency Treatment Performance of
25
26 Acute Cardiovascular and Cerebrovascular Diseases issued by the National Health
27
28 Commission of China in 2015 [15]. Briefly, this flow chart included 1 center (EMS),
29
30 2 types of hospitals (PCI and non-PCI), 3 types of transfer methods (EMS transfer to
31
32 hospital, bypass emergency department (ED) and inter-hospital transfer), and 11
33
34 clinical pathways. Different clinical pathways were selected to execute the optimal
35
36 emergency treatment based on the approaching time, method and hospital ability
37
38 (Fig. 2). In addition, the procedures should be launched without results of myocardial
39
40 biomarkers according to typical ischemic symptoms and electrocardiogram (ECG).
41
42
43
44
45
46
47

48 **Data collection and management**

49
50 Data of all treatment process were collected, including patient general information,
51
52 prehospital treatment, in-hospital management and follow-up management (Table 1).
53
54 Considering the real situation in ED, many time points could not be recorded
55
56 manually on time which might lead to missing and inaccurate data. Mobile device app
57
58
59
60

1
2
3
4 can record these time variables through a simple click and complete the prehospital
5
6 ECG transmission. In addition, the technique of data auto-capture becomes
7
8 more and more popular at present and should resolve this issue. All of these methods
9
10 are considered gradually in this study.
11
12

13
14 Data were inputted into a self-built electronic database together with two existing
15
16 databases of both CPC accreditation and national PCI registry by trained clinical
17
18 research coordinators and clinicians in each hospital. The quality of the data was
19
20 monitored and suspicious contents with missing, outlier and logical errors were
21
22 mainly reviewed. When all problems are resolved, the database is then locked for
23
24 statistical analysis.
25
26
27
28

29
30 The describing method was used in CSCAP to mainly rank data quality and
31
32 medical quality. Continuous variables were described as mean (standard deviation) or
33
34 median (interquartile range), while categorical variables were described as a
35
36 percentage. Multivariate regression model was used to evaluate the factors related to
37
38 the assessment of medical quality. The Cox model was used to analyze the association
39
40 between exposures and medical outcomes. A P value < 0.05 was defined as a
41
42 significant difference. All analyses were performed using R
43
44 (<http://www.R-project.org>).
45
46
47
48
49

50 **Key performance index**

51
52
53 The National Cardiovascular Data Registry (NCDR), established since 1997, has
54
55 become the basis for project implementation and quality evaluation as well as medical
56
57 quality improvement of research centers in the United States. It has a positive impact
58
59
60

1
2
3
4 on clinical practice, medical payment, clinical research and government
5
6 decision-making [24 25]. The present study referred to the NCDR model to optimize
7
8 the STEMI quality of care and established an evaluation, feedback and improvement
9
10 system for primary key performance indexes (KPIs). For KPI selection, PPCI
11
12 hospitals focused on the improvement in the PPCI capacity and efficiency, non-PPCI
13
14 hospitals focused on the improvement in rapid diagnosis, thrombolysis and referral
15
16 capacity to PPCI hospitals, and EMS focused on the improvement in information
17
18 transmission to alert hospitals early for rapid and accurate transfer.
19
20
21
22
23
24

25 A total of 13 primary KPIs were selected for medical quality evaluation based on
26
27 different roles of EMS and hospitals in STEMI management (Table 2). However,
28
29 different treatment delay indexes were used in different phases according to the
30
31 progress of network construction. D2N and D2B time, defined as in-hospital FMC to
32
33 target vessel open, were used to evaluate in-hospital delay in CSCAP-1. First medical
34
35 contact-to-balloon (FMC2B) time and first medical contact-to-needle (FMC2N) time,
36
37 defined as FMC by emergency system or hospital to target vessel open, were used to
38
39 evaluate the whole medical system delay in CSCAP-2. Total ischemic time, defined
40
41 as symptom onset to target vessel open, is used in CSCAP-3 to add the information of
42
43 patient delay.
44
45
46
47
48
49

50 The circular enrollment–evaluation–feedback–improvement method will be
51
52 implemented in both CSCAP-2 and CSCAP-3. The quality feedback report contains
53
54 each KPI of the affiliation and its ranking within its regional network and among all
55
56 affiliations. Comparisons of KPIs with itself and those of others are analyzed for
57
58
59
60

1
2
3
4 tailed improvements.
5
6
7

8 **Patient and public involvement**

9

10 Public education of first aid and health care will be performed during the project
11 implementation. Patients were not offered the opportunity to participate in the study
12 design. They will obtain the information related to the study via public media as well
13 as academic publications.
14
15
16
17
18
19

20 **Ethics and dissemination**

21
22

23 The study was conducted in accordance with Declaration of Helsinki. The study
24 protocol was approved by the Ethics Committee of Peking University First Hospital.
25
26 Ranking reports of quality of care will be made available to all participant affiliations.
27
28 Results will be disseminated at international conferences and published in
29 peer-reviewed scientific journals or public media.
30
31
32
33
34
35
36
37
38
39

40 **Discussion**

41

42 The integration and optimization of an integrated regional network with government
43 support are urgent issues of STEMI care, especially in China. CSCAP is the first
44 prospective registry study focused on regional network construction and will help to
45 understand the current situations and the differences with other countries extensively,
46 which leading to optimized clinical practice and problem-guided improvement. It will
47 provide important information for the network construction shifting from the PPCI
48 hospital-centered regional network to the whole-city network step by step, so as to
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 create an optimal integrate STEMI care system in China.
5
6
7
8

9 **Contributions** Yan Zhang coordinated the study, assisted with data collection,
10 performed data analysis, and drafted the manuscript. Bo Yu, Yaling Han, Jianan
11 Wang, Lixia Yang, Zheng Wan, Zheng Zhang, Yuguo Chen, Xianghua Fu, Chuanyu
12 Gao, Bao Li, Jiyan Chen, Ming Wu, Yitong Ma, Xingsheng Zhao, Yundai Chen,
13 Hongbing Yan, Dingcheng Xiang, Weiyi Fang, and Junbo Ge carried out the data
14 collection and helped draft the manuscript. Sameer Mehta and Christoph K Naber
15 participated in the design and helped draft the manuscript. Yong Huo, principal
16 investigator of the project, conceived and designed the project, helped collect data and
17 draft the manuscript. All authors reviewed the results and approved the final version
18 of the manuscript.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Acknowledgments**

39
40 The authors thank the study team members and patient advisers of all
41 collaborative hospitals and emergency medical services. They are also grateful to the
42 organizational coordination of Chinese Medical Doctor Association and China
43 Cardiovascular Association. They acknowledge the supports provided by the National
44 Health Commission and local governments in China.
45
46
47
48
49
50
51
52
53
54
55

56 **Funding** CSCAP was funded by Sanofi-Aventis, Abbott, and AstraZeneca.
57

58 **Competing interests** None declared.
59
60

1
2
3
4 **Patient consent for publication** Not required.
5

6 **Ethics approval** This study was reviewed and approved by the Ethics Committees
7
8
9 at Peking University First Hospital.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. Stevens W, Peneva D, Li JZ, et al. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. *BMC health services research* 2016;**16**:175.
2. *Report on cardiovascular disease in China*: Encyclopedia of China Publishing house, 2017.
3. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;**127**:e362-425.
4. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *European heart journal* 2012;**33**:2569-619.
5. Eagle KA, Nallamothu BK, Mehta RH, et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. *European heart journal* 2008;**29**:609-17.
6. Song L, Hu DY, Yan HB, et al. Influence of ambulance use on early reperfusion therapies for acute myocardial infarction. *Chinese medical journal* 2008;**121**:771-5.

- 1
2
3
4 7. Li J, Li X, Wang Q, et al. ST-segment elevation myocardial infarction in China
5
6 from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial
7
8 Infarction Study): a retrospective analysis of hospital data. *Lancet*
9
10 2015;**385**:441-51.
11
12
- 13
14 8. Jollis JG, Granger CB, Henry TD, et al. Systems of care for ST-segment-elevation
15
16 myocardial infarction: a report From the American Heart Association's
17
18 Mission: Lifeline. *Circulation. Cardiovascular quality and outcomes*
19
20 2012;**5**:423-8.
21
22
- 23
24 9. Kristensen SD, Fajadet J, Di Mario C, et al. Implementation of primary angioplasty
25
26 in Europe: stent for life initiative progress report. *EuroIntervention : journal of*
27
28 *EuroPCR in collaboration with the Working Group on Interventional*
29
30 *Cardiology of the European Society of Cardiology* 2012;**8**:35-42.
31
32
- 33
34 10. Gao R, Patel A, Gao W, et al. Prospective observational study of acute coronary
35
36 syndromes in China: practice patterns and outcomes. *Heart* 2008;**94**:554-60.
37
38
- 39
40 11. Hao Y, Liu J, Liu J, et al. Rationale and design of the Improving Care for
41
42 Cardiovascular Disease in China (CCC) project: A national effort to prompt
43
44 quality enhancement for acute coronary syndrome. *American heart journal*
45
46 2016;**179**:107-15.
47
48
- 49
50 12. Xu H, Li W, Yang J, et al. The China Acute Myocardial Infarction (CAMI)
51
52 Registry: A national long-term registry-research-education integrated platform
53
54 for exploring acute myocardial infarction in China. *American heart journal*
55
56 2016;**175**:193-201.e3.
57
58
59
60

- 1
2
3
4 13. Pre-hospital medical emergency management measures. *Chinese Village Medicine*
5
6 2014;85-86. (In Chinese)
7
8
9 14. National Health Commission of China. Guiding Principles for Construction and
10
11 Management of Chest Pain Center (Trial). 2017. (In Chinese)
12
13
14 15. National Health Commission of China. The Announcement of Improving Medical
15
16 Emergency Treatment Performance of Acute Cardiovascular and
17
18 Cerebrovascular Diseases. 2015. (In Chinese)
19
20
21
22 16. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial
23
24 infarction. *Circulation* 2012;**126**:2020-35.
25
26
27 17. Chinese Society of Cardiology, Editorial board of Chinese Journal of Cardiology.
28
29 Guidelines for the diagnosis and treatment of acute ST segment elevation
30
31 myocardial infarction. *Chinese Journal of Cardiology* 2015;**43**:380-93. (In
32
33 Chinese)
34
35
36
37 18. Ranasinghe I, Rong Y, Du X, et al. System barriers to the evidence-based care of
38
39 acute coronary syndrome patients in China: qualitative analysis. *Circulation.*
40
41 *Cardiovascular quality and outcomes* 2014;**7**:209-16.
42
43
44
45 19. Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door-to-balloon
46
47 time in acute myocardial infarction. *The New England journal of medicine*
48
49 2006;**355**:2308-20.
50
51
52
53 20. Graff LG, Dallara J, Ross MA, et al. Impact on the care of the emergency
54
55 department chest pain patient from the chest pain evaluation registry
56
57 (CHEPER) study. *The American journal of cardiology* 1997;**80**:563-8.
58
59
60

- 1
2
3
4 21. Windecker S, Bax JJ, Myat A, et al. Future treatment strategies in ST-segment
5
6 elevation myocardial infarction. *Lancet* 2013;**382**:644-57.
7
8
9 22. China Chest Pain Center Accreditation Work Committee. Standard for Chinese
10
11 Chest Pain Center accreditation. *Chinese Journal of Interventional Cardiology*
12
13 2016;**24**:121-30. (In Chinese)
14
15
16 23. China Chest Pain Center Accreditation Work Committee. Standard for Chinese
17
18 Primary Chest Pain Center accreditation. *Chinese Journal of Interventional*
19
20 *Cardiology* 2016;**24**:131-33. (In Chinese)
21
22
23 24. Diercks DB, Kontos MC, Chen AY, et al. Utilization and impact of pre-hospital
24
25 electrocardiograms for patients with acute ST-segment elevation myocardial
26
27 infarction: data from the NCDR (National Cardiovascular Data Registry)
28
29 ACTION (Acute Coronary Treatment and Intervention Outcomes Network)
30
31 Registry. *Journal of the American College of Cardiology* 2009;**53**:161-6.
32
33
34 25. Krim SR, Vivo RP, Krim NR, et al. Regional differences in clinical profile,
35
36 quality of care, and outcomes among Hispanic patients hospitalized with acute
37
38 myocardial infarction in the Get with Guidelines-Coronary Artery Disease
39
40 (GWTG-CAD) registry. *American heart journal* 2011;**162**:988-95. e4.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. CSCAP data elements

Category	Example elements
Patient baseline information	Demographics (age, sex, ethnicity, region, occupation, marriage status, and medical insurance type) Risk factors (smoking status, BMI, hypertension, diabetes, dyslipidemia, chronic kidney disease, peripheral artery disease, MI history, stroke history, and prior revascularization) Clinical presentation (blood pressure, heart rate, and cardiac function classification)
Prehospital information	Patient (symptoms, symptom onset time, and hospital approaching method) EMS (response time, transfer process, first ECG time, ECG transmission ratio, and bypass ED ratio) Non-PCI hospital (hospital approaching method, first medical contact time, admission time, first ECG time, diagnosis time, consent time, reperfusion and other treatment, DI-DO time, and transfer process)
PCI hospital information	Reperfusion (methods, indication and contraindication, and nonreperfusion reasons) Treatment delay (hospital approaching method, first medical contact time, bypass ED ratio, admission time, first ECG time,

1
2
3
4 catheter lab ready time, consent time, D2B, D2N, FMC2B,
5
6 FMC2N, total ischemic time, and reasons of delay)
7
8
9 PCI procedures (operative route, coronary angiography
10
11 results, aspiration, culprit vessels, stent, and elective PCI)
12
13
14 Thrombolytic procedures (thrombolytic agent, dose, and
15
16 outcome)
17
18
19 Medications (loading dose DAPT and statin, antiplatelets,
20
21 β -blockers, statin, ACEI/ARB, GP IIb/IIIa inhibitor, and
22
23 anticoagulant with dose and contraindication information)
24
25
26 Laboratory results (troponin, CK-MB, creatinine, HbA1c,
27
28 fasting glucose, BNP or NT-proBNP, lipid profiles, ECG, and
29
30 UCG)
31
32
33
34 Discharge (diagnosis, in-hospital duration, expense, and
35
36 medications)
37
38
39 Outcomes (death, non-fatal reinfarction, nonfatal stroke,
40
41 revascularization, mechanical complication, and bleeding)
42
43
44
45 Follow-up and management Presentation status (symptom, cardiac function classification,
46
47 blood pressure, heart rate, and follow-up on-time ratio)
48
49
50 Laboratory results (lipid profiles, glucose traits, HbA1c,
51
52 creatinine, hemoglobin, BNP or NT-proBNP, ECG, and
53
54 UCG)
55
56
57 Medications (antiplatelets, β -blockers, statin, and ACEI/ARB)
58
59
60

1
2
3
4 Risk factor control rate (Blood pressure, lipid, glucose, and
5
6 smoking cessation)
7

8
9 Outcomes (death, nonfatal reinfarction, stroke,
10
11 revascularization, rehospitalization due to unstable angina
12
13 pectoris, heart failure or other cardiovascular reasons, and
14
15 bleeding)
16
17
18

19 ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
20
21 BMI, body mass index; BNP, brain natriuretic peptide; CK-MB, creatine kinase MB
22
23 isoenzyme; DAPT, dual antiplatelet therapy; D2B, door to balloon; D2N, door to
24
25 needle; DI–DO, door in–door out; ECG, electrocardiograph; ED, emergency
26
27 department; EMS, emergency medical service; FMC2B, first medical contact to
28
29 balloon; FMC2N, first medical contact to needle injection; GP IIb/IIIa, glycoprotein
30
31 IIb/IIIa; HbA1c, glycosylated hemoglobin A1c; MI, myocardial infarction;
32
33 NT-ProBNP, N-terminal pro–brain natriuretic peptide; PCI, percutaneous coronary
34
35 intervention; UCG, ultrasound cardiogram.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Primary performance measures for evaluating medical care quality

Primary performance measures

Prehospital care

Symptom onset to arrival in hospital (min)

Hospital admission ratio via ambulance (%)

Prehospital ECG transmission ratio (%)

Bypass ED ratio in patients with symptom onset within 12 h (%)

Reperfusion

Overall reperfusion ratio (%)

Thrombolysis ratio in patients with symptom onset within 12 h (%)

Primary PCI ratio in patients with symptom onset within 12 h (%)

D2B in patients with symptom onset within 12 h (min)

D2N in patients with symptom onset within 12 h (min)

DischargeUsage of both DAPT, statin, β blocker, and ACEI/ARB in patients without contraindication (%)**Outcomes**

In-hospital mortality (%)

Follow-up and management

1-Year on-time follow-up ratio (%)

1-Year MACE (%), including mortality, non-fatal myocardial infarction, non-fatal stroke, and hospitalization due to heart failure or acute coronary syndrome

ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;

1
2
3
4 DAPT, dual antiplatelet therapy; D2B, door to balloon; D2N, door to needle; ECG,
5
6 electrocardiogram; ED, emergency department; PCI, percutaneous coronary
7
8
9 intervention; MACE, major adverse cardiovascular event.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


1
2
3
4 **Figure legends**
5


6 Figure 1. CSCAP whole-city STEMI care network construction.
7

8
9 Figure 2. CSCAP STEMI emergency care flow chart.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





PCI, percutaneous intervention

170x148mm (300 x 300 DPI)